

---

# Mortality in rheumatoid arthritis: 2008 update

---

T. Sokka, B. Abelson, T. Pincus

---

Tuulikki Sokka, MD, PhD, Department of Medicine, Jyväskylä Central Hospital, Jyväskylä, Rheumatism Foundation Hospital, Heinola, and Medcare Oy, Äänekoski, Finland;

Benjamin Abelson, BA, Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY, USA; Theodore Pincus, MD, Clinical Professor of Medicine, New York University School of Medicine, and Director of Outcomes Research, NYU Hospital for Joint Diseases, New York, NY, USA.

Dr. T. Sokka received grant support from Central Finland Health Care District and Rheumatism Foundation Hospital EVO-Grants.

Please address correspondence to: Theodore Pincus, MD, Division of Rheumatology, NYU Hospital for Joint Diseases, 301 East 17<sup>th</sup> Street, Room 1608, New York, NY 10003, USA. E-mail: tedpincus@gmail.com

Received and accepted on September 17, 2008.

*Clin Exp Rheumatol* 2008; 26 (Suppl. 51): S35-S61.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2008.

**Key words:** Mortality, rheumatoid arthritis, causes of death, prognostic markers, standard mortality ratios.

Competing interests: none declared.

## ABSTRACT

Mortality rates in patients with rheumatoid arthritis (RA) are 1.5-1.6 fold higher than in the general population, with similar patterns over 60 years. The acute attributed causes of death appear overall similar to the general population, with cardiovascular disease the most common attributed cause of death, and with more infection, pulmonary and renal disease in RA than in the general population. All clinical measures indicating more severe clinical status appear prognostic of premature mortality, with rheumatoid factor and the shared epitope significant for progressive RA. Functional and global measures as well as comorbidities generally are the most significant predictors of premature death.

Mortality rates in patients with rheumatoid arthritis (RA) are elevated compared to the general population (1-124) (Table I). Similar standardized mortality ratios (SMRs) of about 1.2-1.3 in inception cohorts and 1.6-1.7 in non-inception cohorts (Table II) have been seen over 60 years (Table III). The acute attributed causes of death in patients with RA appear overall not unlike those in the general population, with cardiovascular disease the most frequent cause of death, though at an earlier age. Infection, pulmonary and renal disease are more common in RA than the general population as attributed causes of death (Table IV). The pattern of causes of death in RA also has remained similar over the years, and RA usually does not appear on death certificates, even in recent years (Table V). All clinical measures indicating more severe clinical status appear prognostic of premature mortality, with rheumatoid factor significant for progressive RA, and functional and global measures as well as comorbidities generally the most significant predictors of premature death (Table VI).

A clinical rheumatologist with 300 RA patients would see one patient die every

6 weeks, or 8 per year (125), with causes of death seen in Table IV. Evidence of higher mortality rates would not be apparent, unless longitudinal data over 5-20 years were available for comparison to the general population. Such data are not available at most treatment centers, even at this time.

People with RA have higher levels of comorbidities than seen in the general population. Higher rates of infectious, pulmonary and renal disease have been recognized in the pathophysiology of inflammatory rheumatic diseases, and inflammation is now recognized in the pathogenesis of cardiovascular disease (126). When an individual with RA (or any inflammatory rheumatic disease) dies of any cause 5-15 years prior to expected according to that person's age and sex, the death appears in some way related to the inflammatory disease. Therefore, it does not appear informative to attempt to classify causes of death in patients with RA as "related to RA" or "not related to RA."

This review is based on a PubMed search in May 2008, which identified 193 papers for "rheumatoid arthritis" + "mortality," an additional 13 for "rheumatoid arthritis" + "survival" and 25 other reports which were identified from cited reports, for a total of 231 reports (Fig. 1). Among these reports, 124 concerned 84 unique cohorts, which are included in this review. Excluded manuscripts included 7 in languages other than English, 49 addressing outcomes other than mortality and survival in adult RA (laboratory studies without clinical data, drug continuation, surgery results, work disability outcomes, juvenile RA, economic outcomes, family history/cardiovascular outcomes in RA, non-Hodgkin's lymphoma in RA), 14 editorials, 13 letters without data, and 24 reviews.

## Fifteen key points concerning mortality in RA

Extensive data concerning mortality in RA is summarized, as 15 key points.

Supporting evidence is found in the text and tables.

1. RA is associated with increased mortality rates compared to the general population in 78 of 84 cohorts studied; the exceptions may be explained on the basis of a short observation period, inception cohorts with possible inclusion of a higher proportion of individuals with self-limited inflammatory arthritis who met criteria for RA, and/or simple random variation.
2. Median standard mortality ratios (SMRs) for RA compared to the general population have been remarkably similar in the aggregate over the last 60 years, in the range of 1.5-1.6 overall, 1.2-1.3 in inception cohorts and 1.6-1.7 in non-inception cohorts. This observation may be compatible with some improvement in absolute RA mortality outcomes, as survival is greater in the general population, although a widening gap in mortality between patients with RA and the general population has been reported in some locales.
3. Many complexities are seen in analysis of mortality in RA, including the absence of a "gold standard" for diagnosis, and similar clinical findings, including meeting RA classification criteria, in individuals with self-limited polyarthritis and those with progressive RA. Variation in patient populations is seen in different sites, and baseline patient status appears considerably improved at this time compared to previous decades at some sites.
4. Mortality is a lagging indicator, and most published reports necessarily have enrolled patients before the 1990s, prior to early aggressive treatment with methotrexate as a usual practice in many settings, and later availability of biologic agents, so improved mortality outcomes may be anticipated, but only a few reports are available at this time.
5. The attributed causes of death in patients with RA also show remarkably similar patterns in the aggregate over 60 years, both to one another and to the general population. Cardiovascular disease is the most common cause of death, in 40-50% of patients, as in the general population. However, pulmonary, gastrointestinal, renal diseases, and especially infection, are more common as acute attributed causes of death in patients with RA than in the general population.
6. RA is included on the death certificate in fewer than 25% of deaths. Mortality attributable to therapies is seen in fewer than 2% of deaths, although therapies for RA can lead to fatal consequences.
7. Many apparent differences in interpretation of mortality outcomes, rates and predictors may emerge as much from recognized and unrecognized methodological differences as from actual differences. For example, absolute mortality rates generally are higher in men and older patients, while relative mortality rates are generally higher in women and younger patients, in whom the normal population is less likely to experience mortality. Cardiovascular disease is the most common acute cause of death, but infection and pulmonary disease are the causes of death substantially higher in patients with RA than in the general population. As noted, standardized mortality ratios (SMRs) are lower in inception cohorts (both community/population-based and clinic-based) than in non-inception cohorts.
8. Long-term monitoring of patient cohorts is required to recognize possible shortening of lifespan in patients with RA, for comparison with expected survival for individuals matched for age and sex in the general population. However, most rheumatology sites do not collect these data, as important as they may be to justify expensive therapies, document improved outcomes, and raise awareness of RA among health professionals and the general public for greater research support.
9. Premature mortality in patients with RA is predicted by poor status according to almost all measures of clinical status, reflecting an obvious phenomenon that "sicker people are more likely to die." However, depiction of severity in quantitative rather than simple descriptive terms provides more accurate information concerning the risk of mortality for patients and providers of medical care. Quantitative data also allow analyses of whether a change in a measure indicating clinical improvement is associated with improvement in mortality outcomes (as in hypertension).
10. The most significant predictors of premature mortality in patients with RA are older age, male sex, comorbidities, patient and physician global estimates, and poor functional status assessed by physical measures and patient questionnaires. These measures are almost always prognostic of RA mortality at higher levels of significance than radiographs and laboratory tests. However, data concerning functional status have not been included in most reports, even in recent reports.
11. Poor status according to traditional measures, including radiographic scores, ESR, CRP and rheumatoid factor, predicts mortality significantly in many cohorts, although the level of significance generally is lower than for questionnaire measures of physical function and global measures in multivariate analyses. These findings do not reduce the importance of traditional measures to identify individuals with progressive RA and in patient management, but emphasize the greater significance of measures of functional status to predict mortality.
12. Recent reports concerning associations of cardiovascular diseases and mortality in patients with RA with TNF receptors and with the shared epitope at the major histocompatibility locus may provide valuable clues regarding pathogenesis and mechanisms of cardiovascular comorbidity.
13. Socioeconomic status remains a significant indicator of clinical status in RA (and most diseases) and predicts premature mortality in many databases in which a socioeconomic variable is available. However, variables describing socioeconomic status are




Fig. 1. Flow diagram of published reports identified and reviewed.

not included in most reports concerning patients with RA.

14. Therapies for RA, including gold salts, methotrexate and biologic agents, have been reported to be associated with reduced mortality rates in patients with RA, as might be expected, as these therapies are associated with improved values for quantitative prognostic indicators of premature mortality. However, some of these reports involve short-term observations in inception cohorts, in which standard mortality ratios are lower than in non-inception cohorts.
15. Although mortality outcomes do not appear essential to usual patient care, information concerning mortality, and possibly its reduction through

aggressive therapy, may not only improve quality and years of life for current patients with RA, but also promote future advances, as well as interest among the general medical community and general public in further clinical and basic research for people with RA.

This review updates earlier reviews by ourselves (127-132) and others (27,133-139) concerning mortality in RA, and is divided into 5 sections:

- 1) *Rationale to study mortality in RA*
- 2) *Mortality rates in patients with RA*
- 3) *Acute causes of death in RA*
- 4) *Risk factors and predictive markers for mortality in RA*
- 5) *Therapies and mortality in RA*

### 1) Rationale to study mortality in RA

Premature mortality may not appear a primary outcome of interest in care of patients with RA. However, important reasons to study this subject beyond the value for general knowledge and more accurate information for patients and providers of medical care may be cited, including:

- a) Predictors of mortality are also predictors of most long-term outcomes, including work disability, functional declines and costs (140, 141). Therefore, identified markers provide useful targets for therapeutic interventions to improve most outcomes. Many outcomes, such as work disability, joint replacement, costs, etc., may depend to a large extent on societal, economic and medical system variables, rather than effects of disease on a patient. Mortality clearly presents an unequivocally undesirable outcome in any society.

- b) The possibility of identifying “target values” such as a blood pressure of 140/90 in hypertension (142) or a hemoglobin A<sub>1c</sub> level of 7.0% in diabetes (143), which are not necessarily “normal” but “near normal” goals of therapy, might be applied to RA markers (131). Recent emphasis in treatment of RA has appropriately shifted from improvement compared with a placebo to a goal of remission (144), based on a number of clinical trials which documented the value of “tight control” (144-152). Improvement at 20% or 50% (“ACR20” or “ACR50”) (153-156) is not acceptable (145). However, the remission criteria of the American Rheumatism Association (ARA) (157) appear overly stringent (158), as total remission is unusual (159; 160), even with new DMARDs and biologic agents. Efforts to attain complete remission may require unnecessary risks of adverse events in therapy. New definitions of low disease activity and remission in RA according to indices of 3 or 4 measures, including disease activity score 28 (DAS28) (161-163), clinical disease activity index (CDAI) (164, 165) and routine assessment of patient index data 3 (RAPID3) (166, 167),

**Table Ia.** 1953-1980: Studies in rheumatoid arthritis and mortality.

Study	Ref.	Year of study	Location	Study focus	Mean duration of follow-up (years)	Number of patients with RA	Source	Mean age at baseline (years)	Mean disease duration at baseline (years)	SMR (95% CI)
Cobb <i>et al.</i>	(1)	1953	MA, USA	All RA	9.5	583	Clinic	--	--	1.29 (No CI)
Reah	(2)	1963	UK	All RA	13	185	Clinic	--	--	--
Duthie <i>et al.</i>	(3)	1964	UK	All RA	9	307	Rheum Hospital	--	--	2.14 (No CI)
Uddin <i>et al.</i>	(4)	1970	Canada	All RA	10	475	Registry (Queens University, Ontario)	--	--	1.29
Jacoby <i>et al.</i>	(5)	1973	UK	All RA	11 (8-14)	100	Rheum Hospital	51	3 months	1.4 (No CI)
• Rasker and Cosh	(6)	1981		All RA	18					
• Cosh and Rasker	(7)	1982		All RA	20					
• Rasker and Cosh	(8)	1984		All RA	14.6					
• Rasker and Cosh	(9)	1987		All RA	20					
• Reilly <i>et al.</i>	(10)	1990		All RA	25					1.4 (No CI)
• Minaur <i>et al.</i>	(11)	2004		All RA	40					2.13 (1.26-3.60)
Gordon <i>et al.</i>	(12)	1973	Canada	Extraarticular disease	5	127	Clinic	55	11.5	--
Isomäki <i>et al.</i>	(13)	1975	Finland	All RA	3	1000	Rheum Hospital	M: 54.5 F: 55.5	--	--
• Koota <i>et al.</i>	(14)	1977		All RA	5					
• Mutru, <i>et al.</i>	(15)	1985		All RA	10					1.73 (p<0.0001)
• Laakso <i>et al.</i>	(16)	1986		Cancer	10					
• Laakso <i>et al.</i>	(17)	1986		Death certificates	10					
• Laakso <i>et al.</i>	(18)	1986		Renal	10					
• Mutru <i>et al.</i>	(19)	1989		Cardiovascular	10					
Monson and Hall	(20)	1976	MA, USA	All RA	M: 11.4 F: 12.6 (up to 42)	1035	Rheum Hospital	--	--	1.86 (No CI)
Fleming <i>et al.</i>	(21)	1976	UK	All RA	4.5 (up to 15)	102	Clinic	50.5	<1	--
• Corbett <i>et al.</i>	(22)	1993		All RA	12					--
Lewis <i>et al.</i>	(23)	1980	UK	Azathioprine	11	311	Clinic	--	--	1.13 (No CI)
Linos <i>et al.</i>	(24)	1980	MN, USA	All RA	25	521	Population	--	--	1.16 (No CI)

**Table Ib.** 1981-1994: Studies in rheumatoid arthritis and mortality.

Study	Ref.	Year of study	Location	Study focus	Mean duration of follow-up (years)	Number of Patients with RA	Source	Mean age at baseline (years)	Mean disease duration at baseline (3 years)	SMR (95% CI)
Allebeck <i>et al.</i>	(25)	1981	Sweden	All RA	11	293	Population	--	--	M: 1.92 ( $p=0.003$ ) F: 1.18 ( $p=0.11$ )
• Allebeck <i>et al.</i>	(26)	1985		All RA	13					--
Allebeck <i>et al.</i>	(27)	1982	Sweden	All RA	7	1165	Population	--	--	2.48 ( $p<0.001$ )
Scott <i>et al.</i>	(28)	1983	UK	All RA	10	112	Rheum Hospital	--	--	--
Foster <i>et al.</i>	(29)	1984	MA, GA & CO, USA	Scleritis and Keratitis	10	34	Clinic	61.5	12	--
Pincus <i>et al.</i>	(30)	1984	TN, USA	All RA	9	75	Clinic	54.7	11.2	1.92 (1.21-2.78)
• Pincus <i>et al.</i>	(31)	1985		All RA	9					
• Pincus <i>et al.</i>	(32)	1987		All RA	9					
• Pincus <i>et al.</i>	(33)	1994		All RA	15					1.62 (1.12-2.21)
Prior <i>et al.</i>	(34)	1984	UK	All RA	11.2 (3-18)	448	Clinic	43.9	--	199 (No CI)
• Symmons <i>et al.</i>	(35)	1986		All RA	17					2.5 ( $p<0.001$ )
• Symmons <i>et al.</i>	(36)	1998		All RA	21.5					2.7 (2.4-3.1)
Vandenbroucke <i>et al.</i>	(37)	1984	Netherlands	All RA	25	209	Clinic	53.5	8	--
Mitchell <i>et al.</i>	(38)	1986	Canada	All RA	12 (8-16)	805	Clinic	51.8	10	1.51 (No CI)
• Fries <i>et al.</i>	(39)	1985		Cancer	12					
Wicks <i>et al.</i>	(40)	1988	Australia	All RA	32	--	Population	--	--	--
Wolfe <i>et al.</i>	(41)	1988	KS, USA	All RA	3.1	400	Clinic	54.8	9.5	--
Erhardt <i>et al.</i>	(42)	1989	UK	All RA	8 (6-9)	107	Clinic	--	--	--
Saway <i>et al.</i>	(43)	1989	AL, USA	Cervical spine surgery	--	113	Clinic	60	13.9	-
Kazis <i>et al.</i>	(44)	1990	MA, USA	All RA	5	279	Clinic	58	14	--
Lehtinen and Isomäki	(45)	1991	Finland	Intramuscular Gold Therapy	28	573	Rheum Hospital	39.5	2.8	--
Leigh and Fries	(46)	1991	CA, USA	All RA	8	263	Registry	55	13	--
Jacobsson <i>et al.</i>	(47)	1993	AZ, USA	All RA	24	172	Registry	43.8	--	1.28 (1.01-1.62) <sup>a</sup>
Wolfe <i>et al.</i> [includes Wolfe <i>et al.</i> 1988 cohort (41)]	(48)	1994	CA & KS, USA, Canada	All RA	35	3501	Registry (ARAMIS)	53.3	9	2.26 (SEM = 0.05)
Coste and Jouglu	(49)	1994	France	All RA	20	1159	Population	--	--	--

<sup>a</sup> given as mortality rate ratio (MRR).

**Table Ic.** 1995-2000: Studies in rheumatoid arthritis and mortality.

Study	Ref.	Year of study	Location	Study focus	Mean duration of follow-up (years)	Number of patients with RA	Source	Mean age at baseline (years)	Mean disease duration at baseline (years)	SMR (95% CI)
Radis <i>et al.</i>	(50)	1995	PA, USA	Cancer – follow-up study of cyclophosphamide therapy	13.1	a-119 b-119	Clinic	a-54.7 b-55.3	a-9.2 b-9.0	--
Myllykangas-Luosujärvi <i>et al.</i>	(51)	1995	Finland	All RA	--	1666	Population	--	M: 14.0 F:17.4	1.37 (1.35-1.40)
• Myllykangas-Luosujärvi <i>et al.</i>	(52)	1995		Cardiovascular						--
• Myllykangas-Luosujärvi <i>et al.</i>	(53)	1995		Cancer						--
• Neva <i>et al.</i>	(54)	2001		Cervical spine disorders						--
Heliövaara <i>et al.</i>	(55)	1995	Finland	All RA	--	175	Population	--	--	--
Jones <i>et al.</i>	(56)	1996	UK	Immuno-suppressive therapy	10	259	Registry	58.6 (median)	--	--
Voskuyl <i>et al.</i>	(57)	1996	Netherlands	Rheumatoid vasculitis	--	244	Clinic	62 (median)	9 (median)	--
Callahan <i>et al.</i>	(58)	1996	CA, FL, ID, PA, TN, MN and DC, USA	All RA	5	Registry (15 private practice) 1378	Clinic	56.6	11.7	1.54 ( $p<0.001$ )
• Pincus <i>et al.</i>	(59)	2004		All RA	10					1.6 ( $p<0.001$ )
Swinson <i>et al.</i>	(60)	1997	UK	Bronchiectasis	5	32	Registry	59.5	10.7	0.9 (0.1-2.5)
Callahan <i>et al.</i>	(61)	1997	TN, USA	All RA	5	210	Clinic	56.6	9.7	1.61 (No CI)
Kremer, Joel	(62)	1997	--	Methotrexate	13.3	29	Clinic	60.6	31.4	--
Wallberg-Jonsson <i>et al.</i>	(63)	1997	Sweden	All RA	15	606	Clinic	M: 56 F: 54	12.5	1.57 ( $p<0.001$ )
Soderlin <i>et al.</i>	(64)	1998	Finland	All RA	5	103	Registry	59.5	18.4	--
van den Borne <i>et al.</i>	(65)	1998	Netherlands	Cyclosporine-A	4.7	208	Registry	55	5.7	--
Lindqvist and Eberhardt	(66)	1999	Sweden	All RA	5	183	Clinic	51	11 months	0.87 (0.53-1.36)
Turesson <i>et al.</i>	(67)	1999	Sweden	Extraarticular disease	--	489	Clinic	68.4	14.2	1.82 (1.48-2.16)
Sokka <i>et al.</i>	(68)	1999	Finland	All RA	11 (8-14)	135	Clinic	50.5	6.5 months	1.28 (.83-1.89)
Gabriel <i>et al.</i>	(69)	1999	MN, USA	All RA	15.1	425	Population	60.2	--	1.38 (1.22-1.55)
Maiden <i>et al.</i>	(70)	1999	UK	All RA	12	200	Clinic	57 (median)	7 (median)	--
Wallberg-Jonsson <i>et al.</i>	(71)	1999	Sweden	All RA	21	211	Clinic	51.9	≤1	--
Krause <i>et al.</i>	(72)	2000	Germany	Methotrexate	10	256	Clinic	64.3	8.5	2.60 (2.05-3.15)
Kvalvik <i>et al.</i>	(73)	2000	Norway	All RA	16	147	Rheum Hospital	58	4.1	149 (1.15-1.88)
Kroot <i>et al.</i>	(74)	2000	Netherlands	All RA	10	622	Clinic	53.3	--	--

**Table Id.** 2001-2002: Studies in rheumatoid arthritis and mortality.

Study	Ref.	Year of study	Location	Study focus	Mean duration of follow-up (years)	Number of patients with RA	Source	Mean age at baseline (years)	Mean disease duration at baseline (years)	SMR (95% CI)
Riise <i>et al.</i>	(75)	2001	Norway	Atlantoaxial subluxation	17	187	Clinic	56.9	10.3	2.00 <sup>a</sup> (1.6-2.5)
Chehata <i>et al.</i>	(76)	2001	UK	All RA	14	309	Rheum Hospital	53	2.5 (median)	1.65 (1.34-1.98)
Isaacs <i>et al.</i>	(77)	2001	UK	Lymphopenia	5.9	53	Clinic	54	9 (median)	1.45 (0.65-3.13) <sup>a</sup>
• Lorenzi <i>et al.</i>	(78)	2008	UK	Lymphopenia	11.8					1.20 (0.72-1.98) <sup>a</sup>
Martínez <i>et al.</i>	(79)	2001	Spain	All RA	9	182	Clinic	M: 57.7 F: 55.8	--	1.85 (No CI)
Riise <i>et al.</i>	(80)	2001	Norway	All RA	6.1	241	Clinic	62.3	--	8 (3-25) <sup>a</sup>
Uhrin <i>et al.</i>	(81)	2001	CA, USA	Lymphoid irradiation	a-11.2 b-9.2	a-53 b-106	a-Clinic b-Registry	a-61.9 b-62.0	a-21.1 b-20.4	--
Chevrel <i>et al.</i>	(82)	2001	France	All RA	--	15	Clinic	41	--	--
Doran <i>et al.</i>	(83)	2002	MN, USA	All RA	14.2	609	Population	58	--	1.27 (1.13-1.41)
• Gabriel <i>et al.</i>	(84)	2003		All RA	14.2	609		58	--	1.27 (1.13-1.41)
• Turesson <i>et al.</i>	(85)	2002		All RA	14.8	424		60	--	--
• Maradit Kremers <i>et al.</i>	(86)	2004		Cardiovascular/ BMI	14.7	603		58	--	--
• Maradit Kremers <i>et al.</i>	(87)	2005		Cardiovascular	15.0	603		58	--	--
• Maradit Kremers <i>et al.</i>	(88)	2005		Sudden death	14.7	603		58	--	--
• Nicola <i>et al.</i>	(89)	2006		Comorbidities	12.7	603		58	--	--
Yelin <i>et al.</i>	(90)	2002	CA, USA	All RA	8.4	1269	Registry	56.7	11.1	1.32
Choi <i>et al.</i>	(91)	2002	KS, USA	Methotrexate	6	1240	Clinic	--	--	--
Bjornadal <i>et al.</i>	(92)	2002	Sweden	All RA	31	46,917	Population	--	--	2.03 (2.00-2.05)
Mikuls <i>et al.</i>	(93)	2002	IA, USA	All RA	13.4	158	Population	67.8	13.4 months	1.52 (1.05-2.20) <sup>b</sup>
Peltomaa <i>et al.</i>	(94)	2002	Finland	All RA	a-12.2 b-7.7	150 a-87 b-63	Clinic	a-46.5 b-59.0	a-7.6 b-5.7 months	1.33 (0.85-1.98) a-0.93 (0.37-1.92) b-1.62 (0.95-2.60)
Goodson <i>et al.</i>	(95)	2002	UK	All RA	6.9	575	Registry (Norfolk Arthritis Registry)	57	6.6 months	M: 1.08 (0.78-1.47) F: 0.99 (0.71-1.33)
• Farragher <i>et al.</i>	(96)	2007	UK	Cardiovascular	10.3	1098				
• Farragher <i>et al.</i>	(97)	2008		HLA	11.4	751		55	5	--
• Naz <i>et al.</i>	(98)	2008		All RA	11.4	499		55	5	1.06 (0.93 - 1.21)

<sup>a</sup>given as mortality rate (MRR); <sup>b</sup>given as hazard ratio (HR).

**Table Ie.** 2003-2005: Studies in rheumatoid arthritis and mortality.

Study	Ref.	Year of study	Location	Study focus	Mean duration of follow-up (years)	Number of patients with RA	Source	Mean age at baseline (years)	Mean disease duration at baseline (years)	SMR (95% CI)
Watson <i>et al.</i>	(99)	2003	UK	Cardiovascular	M: 4.7 F: 4.8	11,633	Registry (General Practice Research Database)	54.5 (m) 57.2 (f)	--	1.6 (1.6-1.6) <sup>a</sup>
Navarro-Cano <i>et al.</i>	(100)	2003	TX, USA	All RA	6.3	779	Clinic	54 (living); 67 (dead)	11 (living); 16 (dead)	--
Thomas <i>et al.</i>	(101)	2003	UK	All RA	19	20,875	Population	58.1	--	M: 2.07 (2.01-2.13) F: 1.97(1.93-2.01)
Wolfe <i>et al.</i>	(102)	2003	KS, USA	All RA	15	1387	Clinic	55.5	7.1	--
• Ang <i>et al.</i>	(103)	2005	--	Depression	18	1290	Rheum Hospital	55.3	6.6	--
Solomon <i>et al.</i>	(104)	2003	MA, USA	Cardiovascular	21	2170 (all women)	Registry (Nurses' Health Study)	58	--	--
Sihvonen <i>et al.</i>	(105)	2004	Finland	All RA	11	604	Population	59	15	1.78 (1.34-2.31) <sup>b</sup>
• Sihvonen <i>et al.</i>	(106)	2005			12					--
• Sihvonen <i>et al.</i>	(107)	2006			12					--
Krishnan <i>et al.</i>	(108)	2004	CA, USA	Cardiovascular	17	3862	Registry (ARAMIS)	56	9.7	--
Sokka <i>et al.</i>	(109)	2004	Finland	All RA	2	1095	Clinic	62.4	11.3	--
• Kauppi <i>et al.</i>	(110)	2005		All RA						--

<sup>a</sup>given as given as mortality rate ratio (MRR), <sup>b</sup>given as hazard ratio (HR).

may provide realistic therapeutic targets (168). Long-term observations regarding values for these indices and individual clinical variables, including joint counts, radiographs, laboratory tests and patient questionnaire measures that are not necessarily totally normal, but result in a prognosis for long-term mortality outcomes similar to the general population, would be informative. These data would help the clinician to balance “tight control” to provide pragmatic target values for therapeutic goals toward improved mortality outcomes.

c) Information concerning mortality outcomes and possible improvement with treatment of RA may provide an important impetus to increase interest of primary care physicians

and the general public. Even today, most health professionals are unaware that the natural history of RA (and other rheumatic diseases) includes premature mortality. Interest in treatment of hypertension, diabetes and hypercholesterolemia was advanced greatly by documentation that treatment not only improved measures indicating a dysregulation (blood pressure, cholesterol), but also improved mortality outcomes. Similar data for RA could raise the profile for treatment in the medical community and the general public.

## 2) Mortality rates in patients with RA

Eighty-four cohorts of patients with RA have been reported with analyses of mortality outcomes (1-124), including

40 reported more than once (Table I, organized according to 84 cohorts) (Fig. 1). The median standardized mortality ratio (SMR) of 57 reports from 1953-2008 was 1.54, including 1.62 in 15 reports from 1953-1989, compared to 1.52 in 14 reports from 1990-2000, and 1.54 in 28 reports from 2001-2008 (Table II). The median SMR was 1.31 (mean 1.29) in 6 community/population-based inception cohorts and 1.28 (mean 1.23) in 5 clinic-based inception cohorts, compared to 1.63 (mean 1.72) in 12 community/population-based non-inception cohorts and 1.65 (mean 1.74) in 19 clinic-based non-inception cohorts (Table II). The median SMR in inception cohorts remained remarkably stable at 1.28 (mean 1.25) from 1953-2008, and in non-inception cohorts fell slightly from 1.86 in 1953-1994, to 1.61 in



**Table If.** 2005-2008: Studies in rheumatoid arthritis and mortality.

Study	Ref.	Year of study	Location	Study focus	Mean duration of follow-up (years)	Number of patients with RA	Source	Mean age at baseline (yr)	Mean disease duration at baseline (yr)	SMR (95% CI)
Book <i>et al.</i>	(111)	2005	Sweden	All RA	20	152	Clinic	61	12	1.56 (128-188)
Goodson <i>et al.</i>	(112)	2005	UK	Cardiovascular	11.4	1010	Registry (Stockport Rheumatology Clinic, Office for National Statistics)	60.4	--	M: 1.45 (1.22-1.71); F: 1.84 (1.64-2.05)
Hakoda <i>et al.</i>	(113)	2005	Japan	All RA	17.8	91	Registry (Radiation Effects Research Foundation)	56.8	8.8	1.6 (1.29-1.99) <sup>b</sup>
Escalante <i>et al.</i>	(114)	2005	TX, USA	Body mass index	7	779	Clinic	55.6	11.06	--
Ronkainen <i>et al.</i>	(115)	2006	Finland	Cervical spine disorders	7.5	86	Clinic	61.8	23.6	--
Carmona <i>et al.</i>	(116)	2007	Spain	Anti-TNF	5	B-789 E-789	Drug Registry (BIOBADASER) Clinic (EMECAR)	B-59 E-61	10 10	B-0.516 (0.315-0.797) <sup>c</sup> E-1.493 (1.174-1.872)
• Abasolo <i>et al.</i>	(117)	2007		Cancer	5	E-789	Clinic (EMECAR)	E-61	10	1.00 (0.50-1.70) <sup>d</sup>
Jacobsson <i>et al.</i>	(118)	2007	Sweden	Anti-TNF	4	1430	Registry (South Swedish Arthritis Treatment Group)	57.8	13.2	1.56 (1.26-1.86)
Gonzalez <i>et al.</i>	(119)	2007	MN, USA	All RA	11.7	822	Population	57.6	--	1.35 (1.23-1.49)
Gonzalez-Gay <i>et al.</i>	(120)	2007	Spain	Cardiovascular /HLA	13.4	182	Clinic	59.7	10.5	--
Young <i>et al.</i>	(121)	2007	UK	Cardiovascular	9.1	1429	Clinic	55.2	6 months	1.27 (1.04-1.46)
• Matthey <i>et al.</i>	(122)	2007	UK	All RA	18	767	Clinic	--	6 months	--
Matthey <i>et al.</i>	(123)	2007	UK	All RA	13	401	Clinic	59.4	9.5	--
Nikolaisen <i>et al.</i>	(124)	2008	Norway	Anemia	6.2	111	Clinic	61 (median)	4.5 (median)	--

<sup>b</sup>given as hazard ratio (HR); <sup>c</sup>all patients on biologics; <sup>d</sup>SMR for cancer.

1995-2001, and 1.61 in 2002-2008. The median SMR in inception cohorts was 1.28 in those maintained over 6-12 years compared to 1.39 in those maintained over >12 years, while the SMR was at similar levels, 1.59-1.82, according to period of observation in the 32 non-inception cohorts (Table III). These data extend the observations of Ward (136), who concluded that the primary basis for suggestions of improved mortality outcomes in RA in some recent reports was based on their being inception co-

horts rather than non-inception cohorts. Six reports (24, 60, 66, 74, 94, 95) indicated that mortality rates were not increased compared to the general population. Two were based on a mean of 5 years of observation (60, 66). Another was based on median 5.8 years observation (although the title states "up to 10 years") (74). A fourth study was based on a mean of 6.9 years of observation and included all patients from an early arthritis clinic with inflammatory polyarthritis, of whom only 29% were

positive for rheumatoid factor (95). A fifth was a population-based study indicating an SMR of 1.16 (24), interpreted as not significant, but later recalculated and interpreted as significant (84). The sixth study indicated an increase in mortality rates that was not statistically significant: an SMR of 1.62 in one of two cohorts was balanced by an SMR of 0.93 in the second cohort (94). Several reports from other cohorts suggested that mortality rates in RA were not increased until after 8-10 years (84) and

were increased with increasing duration of disease (36, 48, 92), although excess mortality within 3 years (22) and 7 years (121) has been reported. While variation in certain settings may be seen, overall SMR levels do not differ substantially according to the period of observation (Table III).

Forty-four specialized studies have been focused on three domains: 18 focused on specific causes of death, including 11 on cardiovascular death (19, 52, 86, 87, 96, 99, 104, 108, 112, 120, 121), 4 on cancer (16, 39, 50, 117), and 1 each on renal death (18), sudden death (88), and death certificates (17); 16 focused on comorbidities and disease features, including 4 on cervical spine disorders (43, 54, 115, 169), 2 on extraarticular disease (12, 67), 2 on lymphopenia (77; 78), 2 on body mass index (114, 119), and 1 each on general comorbidities (89), depression (103), vasculitis (57), scleritis/keratitis (29), anemia (124), and bronchiectasis (60); and 10 focused on therapies, including 3 on methotrexate (62, 72, 91), 2 on anti-TNF biological agents (116, 118), and 1 each on intramuscular gold (45), azathioprine (23), cyclosporine-A (65), immunosuppressive therapy (56), and follow-up of lymphoid irradiation (81).

Some variation has been seen among different cohorts, explained in part by different patient populations, different treatment philosophies at different sites, and many other factors. Although SMR levels have not changed substantially over half a century of observation, most patients were entered into these databases prior to modern early aggressive therapy with methotrexate. In one report suggesting a widening gap in mortality rates between people with RA and the general population (119), all patients were entered prior to 1995, with hydroxychloroquine reported in 2004 as a mainstay of therapy (170), and may not reflect advances in therapy with methotrexate, and later biological agents. Considering differences in populations in severity, duration at baseline, treatments and other variables, the authors would interpret data concerning the 84 cohorts as showing relatively similar patterns, suggesting a shortening of lifespan of 4-10 years

relative to expected mortality according to age and sex (51, 171).

Several important limitations are seen in the analysis of mortality in RA (Table VII):

*a) No "gold standard" for diagnosis.*

Analysis of mortality in RA is similar in some respects to analyses in other chronic diseases such as hypertension or hyperlipidemia (172). Each of these diseases is characterized by a dysregulation, which in itself is not necessarily harmful to the patient, but a natural history in which the dysregulation leads to long-term damage. Excellent therapies have been developed for these diseases, which do not "cure" the dysregulation but "control" its consequences and prevent organ damage, such as vascular disease or joint destruction. Without a "cure," generally there is a need for ongoing (often lifetime) medication, which may improve mortality outcomes.

However, unlike hypertension or hypercholesterolemia, no single "gold standard" is available in RA for diagnosis, monitoring and prognosis. Markers such as rheumatoid factor and antibodies to cyclic citrullinated peptides (CCP) are positive in a majority, but only two-thirds of patients with RA (173). Furthermore, 40% of patients have a normal erythrocyte sedimentation rate (ESR) on presentation (174). Classification criteria for RA have been invaluable to provide relatively uniform cohorts for clinical trials and clinical research. However, a diagnosis of RA remains based primarily on the judgment of a physician, hardly as precise as a single diagnostic marker. This matter complicates analyses of mortality in RA and most rheumatic diseases.

*b) Self-limited early inflammatory arthritis.*

One consequence of complexity in the diagnosis of RA is that many people with signs of early inflammatory arthritis have a self-limited rather than progressive disease. This matter further complicates efforts to analyze populations for the incidence, prevalence, long-term course, morbidity and mortality in

RA. This phenomenon was documented in the 1960s and 1970s, in population-based studies in which all individuals in an area were analyzed to recognize those who met ARA criteria for RA (175). In longitudinal studies in Massachusetts and Michigan, only 25% who initially met RA criteria still had evidence of RA 3-5 years later (176-178). Furthermore, in population-based studies in Wensleydale, England (179), Tecumseh, Michigan (180), Jerusalem, Israel (181), Montana and Arizona in the U.S. (182), and Heinola, Finland (183), only about 25% of individuals among all who met RA criteria had rheumatoid factor [summarized in (184)].

Similar data have emerged more recently from early arthritis clinics, in which about 50% of people with early inflammatory arthritis are found to have a progressive disease (185-187). Although anti-CCP and rheumatoid factor identify a high likelihood of progressive RA, about one-third of patients with progressive disease are negative for these markers, as noted above (173). Therefore, all series of patients with RA are "contaminated" in part with some proportion of patients who do not have a progressive inflammatory arthritis. Probably many people with an early self-limited transient polyarthritis never see a physician before the problem is resolved. This phenomenon may explain why the median SMR in inception cohorts is 1.31 compared to 1.63 in non-inception cohorts (Tables II and III).

*c) Patient characteristics vary considerably in different cohorts.*

Patients with RA differ considerably in clinical manifestations and severity, both within clinical settings and between different settings, in part due to uncertainty concerning diagnosis, but also even in "classical" presentations. Variation may be seen in many characteristics, including whether patients present in early arthritis clinics versus usual clinical settings, tertiary care centers that serve an entire region versus limited areas, severity of clinical status at baseline observation,

**Table II.** Standard mortality ratios (SMR) in 18 community/population-based cohorts and 24 clinic-based cohorts of patients with rheumatoid arthritis.

COMMUNITY/POPULATION-BASED COHORTS				CLINIC-BASED COHORTS			
Study	Ref.	no.	SMR	Study	Ref.	no.	SMR
INCEPTION COHORTS (n=6)				INCEPTION COHORTS (n=5)			
Linos <i>et al.</i> 1980	(24)	521	1.16	Jacoby <i>et al.</i> 1973	(5)	100	1.4
Gabriel <i>et al.</i> 1999	(69)	425	1.38	Lindqvist & Eberhardt 1999	(66)	183	0.87
Mikuls <i>et al.</i> 2002	(93)	158	1.52	Sokka <i>et al.</i> 1999	(68)	135	1.28
Goodson <i>et al.</i> 2002	(95)	575	1.06	Peltomaa <i>et al.</i> 2002	(94)	150	1.33
Doran <i>et al.</i> 2002	(83)	609	1.27	Young <i>et al.</i> 2007	(121)	1429	1.27
Gonzalez <i>et al.</i> 2007	(119)	822	1.35				
			Median 1.31 Mean 1.29				Median 1.28 Mean 1.23
NON-INCEPTION COHORTS (n=12)				NON-INCEPTION COHORTS (n=19)			
Uddin <i>et al.</i> 1970	(4)	475	1.29	Cobb <i>et al.</i> 1953	(1)	583	1.29
Allebeck <i>et al.</i> 1981	(25)	193	1.92	Duthie <i>et al.</i> 1964	(3)	307	2.14
Allebeck <i>et al.</i> 1982	(27)	1165	2.48	Isomäki <i>et al.</i> 1975	(13)	1000	1.73
Jacobsson <i>et al.</i> 1993	(47)	172	1.28	Monson & Hall 1976	(20)	1035	1.86
Myllykangas-Luosujärvi <i>et al.</i> 1995	(51)	1666	1.37	Lewis <i>et al.</i> 1980	(23)	311	1.13
Bjornadal <i>et al.</i> 2002	(92)	46917	2.03	Pincus <i>et al.</i> 1984	(30)	75	1.92
Watson <i>et al.</i> 2003	(99)	11633	1.6	Prior <i>et al.</i> 1984	(34)	448	1.99
Thomas <i>et al.</i> 2003	(101)	2003	2.02	Mitchell <i>et al.</i> 1986	(38)	805	1.51
Sihvonen <i>et al.</i> 2004	(105)	604	1.78	Wolfe <i>et al.</i> 1994	(48)	3501	2.26
Goodson <i>et al.</i> 2005	(112)	1010	1.65	Callahan <i>et al.</i> 1996	(58)	1416	1.54
Hakoda <i>et al.</i> 2005	(113)	91	1.6	Callahan <i>et al.</i> 1997	(61)	210	1.61
Jacobsson <i>et al.</i> 2007	(118)	1430		Wallberg-Jonsson <i>et al.</i> 1997	(63)	606	1.57
			Median 1.63 Mean 1.72	Krause <i>et al.</i> 2000	(72)	256	2.6
				Kvalvik <i>et al.</i> 2000	(73)	147	1.49
				Riise <i>et al.</i> 2001	(75)	187	2
				Chehata <i>et al.</i> 2001	(76)	309	1.65
				Martínez <i>et al.</i> 2001	(79)	182	1.85
				Yelin <i>et al.</i> 2002	(90)	1269	1.32
				Book <i>et al.</i> 2005	(111)	152	1.56
							Median 1.65 Mean 1.74

**Table III.** Standard mortality ratios (SMRs), in rheumatoid arthritis cohorts according to community or clinic, period of observation, and year of report, classified for inception cohorts and non-inception cohorts.

	INCEPTION COHORTS			NON-INCEPTION COHORTS		
	no.	Median	Mean	no.	Median	Mean
<i>Source of patients</i>						
Community/population-based	6	1.31	1.29	14	1.63	1.73
Clinic-based	5	1.28	1.23	17	1.65	1.73
<i>Period of Observation</i>						
< 6 years	1	0.87	0.87	5	1.60	1.66
6 - 12 years	6	1.28	1.26	16	1.82	1.78
> 12	4	1.39	1.37	10	1.59	1.68
<i>Year of Report</i>						
1953-1994	2	1.28	1.28	13	1.86	1.75
1995-2001	3	1.28	1.18	9	1.61	1.74
2002-2008	6	1.30	1.30	9	1.61	1.68
<b>Total</b>	<b>11</b>	<b>1.31</b>	<b>1.30</b>	<b>31</b>	<b>1.63</b>	<b>1.73</b>

and many others. Wide variations in DAS and HAQ scores in different countries have been reported in the multinational QUEST-RA database (188), with mean low disease activity levels in such countries as the Netherlands, Finland and the U.S., but high activity in such countries as Serbia, Poland, Latvia. Furthermore, formal education level has been found in several settings to be a more significant identifier of good versus poor clinical status than age or duration of disease (189).

- d) *Different reference mortality rates.* Differences in SMRs across studies may result from the choice of reference mortality rates. For example, if observed RA deaths were ascertained between 1960-2000, and expected deaths were derived using mortality rates between 1980-2000, then SMR may appear worse than using rates derived from 1960-2000 (assuming that mortality improved over time).
- e) *Changing natural history of RA.* A number of reports suggest that the status of patients with RA is considerably improved in recent years compared to 2-3 decades earlier, in terms of functional status, radiographic scores, level of erythrocyte sedimentation rate (ESR), number of swollen joints, and other variables (190). Improved clinical status may have many bases, including a change in treatment philosophy from relatively indolent to aggressive early therapy, use of methotrexate and other DMARDs early in disease (191). In addition, some reports suggest that RA may be becoming a milder disease in general (192), similar to cardiovascular disease (193). The improved clinical status of patients according to measures associated with a higher likelihood of premature mortality might be anticipated to be translated into improved mortality outcomes, which have been reported in some locales (62, 72, 91, 116, 193, 194), but not in others (119).
- f) *Period of observation.* As noted above, increased mortality rates were seen in some studies after 3 or 7 years of disease (22, 121), while

other reports suggest that highest increased mortality rates are seen after 8-10 years (84), and even later in disease course (36, 48, 92). Overall, median SMR appear similar according to the period of observation. The influence of RA variables on mortality in general is most marked in periods of 5-20 years. After 15-20 years, the impact of age and gender become predominant, and ultimately SMR approaches 1.0 (as everyone ultimately dies).

- g) *Limited resources for study.* Resources for studies of mortality in RA are considerably less than support for studies of mortality associated with hypertension and hyperlipidemia, based on higher prevalence and recognized pathophysiologic consequences of possible sudden cardiac death not seen in RA. Incentives in RA (and other rheumatic diseases) are lesser than in cardiovascular and neoplastic diseases to support large-scale studies to document favorable mortality effects of therapies by publicly funded agencies and/or pharmaceutical companies. Therefore, cost-effective strategies to study mortality outcomes, risk factors, and possible benefits of interventions in RA are needed, through data collected at many clinical settings (195).
- h) *Absence of long-term clinical trials.* RA is a symptomatic disease, in contrast to hypertension and hyperlipidemia, which generally are asymptomatic. In asymptomatic diseases, it was reasonable to conduct randomized controlled clinical trials to determine whether a therapy (which could lead to adverse events) may or may not favorably affect long-term mortality outcomes. Such trials have indicated that "tight control" of hypertension, hyperlipidemia or diabetes results in improved mortality outcomes (196-198). In a symptomatic disease such as RA, it is ethically and logistically impossible to conduct long-term randomized controlled clinical trials of mortality outcomes (199), particularly with evidence over the last two decades that "tight control" with

methotrexate and other DMARDs as well as biologic agents is associated with prevention of long-term joint damage (144-152). Therefore, possible evidence of improved mortality outcomes must necessarily be derived from longitudinal databases rather than randomized trials, which lead to intrinsically less precise estimates than in hypertension or hyperlipidemia.

- i) *Numbers used to describe risk.* Several complexities in the literature used to describe mortality rates in different cohorts remain incompletely understood by health professionals. For example, the absolute risk of death in almost all series of patients with RA is greater in older people and in males. However, the relative risk of death generally is higher in younger people and females (who have a lower absolute risk of death in the general population). Thus, the same data can be interpreted as indicating greater mortality rates in men or women, or younger or older individuals, depending on whether absolute or relative risk is reported. The SMR differs substantially in inception cohorts versus non-inception cohorts (Tables II and III), but conclusions again may appear superficially conflicting, or consistent, depending on the analyses chosen.

Despite these complexities, the similarity of patterns of increased mortality rates over the years provides rather robust conclusions concerning premature mortality in RA.

### 3) Acute causes of death in RA

The acute attributed causes of 33,250 deaths in 50 published reports (of 54 cohorts) of patients with RA in the United States and Western European countries, in which most series were compiled, indicate quite similar patterns (Tables IV and V). Cardiovascular disease was the acute attributed cause of death in 39.6% of patients, compared to cancer in 16.8%, renal disease in 5.8%, respiratory disease in 9.0%, infection in 14.3%, gastrointestinal disease in 5.1%, sudden death in 3.1%, accidents/intoxication in 4.2%, musculoskeletal disease or rheumatoid arthritis in 9.4%, and

“other causes” in 12.9%. These proportions also appear similar over the years, including 14 reports/cohorts from 1953-1989, 9 reports/cohorts from 1990-2000, 10 reports of 11 cohorts from 2001-2008, as well as 10 reports of 13 specialized cohorts involving results of particular therapies or a focus on a specific outcome, and 7 studies of population cohorts (Table V). The data appear quite similar to a compilation prepared 22 years ago in 1986 (127).

RA or musculoskeletal disease was included as an acute attributed cause of death or listed on death certificates in 12.9% of patients in 1953-1989, 8.3% in 1990-2000, 6.5% in 2001-2008, 4.1% in specialized studies, and 9.2% in population studies (Table V). These data may be explained in part on whether cause of death data were derived from death certificates, which has been more likely in recent years, or from review of a medical record, which was more common in earlier years. Nonetheless, these data suggest that the increased mortality rates in RA remain at least as underrecognized in the medical community as two decades earlier (127).

**Cardiovascular disease.** Cardiovascular disease was the most common cause of death, listed as the cause of 39.6% of all 33,250 deaths, including 39.6% in 1953-89, 46.7% in 1990-2000, 38.6% in 2001-08, 33.5 in specialized studies (some of which were focused on cancer or renal disease) and 43.5% in population studies. These data are similar to the general population, in which 41.0% of deaths in 1977 (127) and 38.3% in 2005 ([http://www.cdc.gov/nchs/data/dvs/LCWK9\\_2005.pdf](http://www.cdc.gov/nchs/data/dvs/LCWK9_2005.pdf)) were attributed to cardiovascular disease (Table V). Therefore, the proportion of cardiovascular deaths among RA patients is not substantially higher than in the general population, but patients die at an earlier age, indicating that RA may be regarded as a risk factor for premature cardiovascular disease and cardiovascular death. As noted above, the relative risk of cardiovascular death is highest in younger patients under the age of 50, whereas the highest absolute risk is seen older patients over the age of 75 (104). Nicola *et al.* (89) reported that congestive heart failure, rather than ischemic heart

disease, is an important contributor to excess mortality in patients with RA, not because of greater severity, but higher frequency.

As discussed in greater detail in the chapter on cardiovascular disease in RA (126), traditional cardiovascular risk factors are increased in patients with RA, including hypertension and smoking. Non-traditional risk factors related to inflammation, including C-reactive protein (CRP) (200) and persistently high disease activity (88), also are associated with cardiovascular mortality in patients with RA. One study indicated that 30-day mortality following myocardial infarction was higher in RA patients than in the general population (88). Krishnan *et al.* describe declines in mortality from myocardial infarction in patients with RA (108), although Naz and Symmons suggested that RA patients do not appear to enjoy the benefits of decreased mortality from cardiovascular disease in the general population (139). Some improvement in mortality is not necessarily incompatible with a widening mortality gap between people with RA and the general population (119).

**Infection.** Infection is the acute cause of death with highest increased frequency in RA patients compared to the general population (Tables IV and V): 14.3% in patients with RA compared to 1.0% in the U.S. population in 1977 and 4.4% in 2005 (suggesting an older population and/or more accurate reporting in 2005). The proportion of deaths attributed to infection has not changed substantially over the years, and was similar to recent years in the era prior to treatment with methotrexate and biologic agents.

**Other causes of death.** Higher mortality rates are also seen for pulmonary, renal and gastrointestinal diseases in patients with RA compared to the general population (Tables IV and V). The proportion of deaths attributed to renal disease was due in large part to high levels of amyloidosis in Finland (18, 45), and fell in recent years. A concomitant lesser likelihood of most cancers is seen, but not of lymphoma and lung cancer, which appear increased as attributable causes of death in patients

with RA (201-203). A lower proportion of deaths is attributed to accidents, presumably as patients with RA are less likely to engage in activities posing a danger to life.

**Complexities in analysis.** Complexities in the analysis of causes of death in RA (Table VII) include:

- a) *Source of information: death certificate or medical record.* The source of information may be a death certificate or a medical record. A death certificate is often completed by a non-rheumatologist attending the patient's demise and may omit mention of RA, whereas an analytic review of a medical record by a rheumatologist may more likely include mention of RA. These differences may lead to different estimates of causes of deaths.
- b) *Underestimation of RA as associated with premature mortality.* Limited knowledge of RA as associated with premature mortality may result in underestimation of RA on a death certificate. For example, a patient with RA who dies of myocardial infarction is less likely than someone known to have suffered from hypertension or diabetes to have their chronic condition listed as “contributory” to cardiovascular death.
- c) *Differences in reporting in different series.* Classification is complicated by differences in reporting in different series. For example, cardiovascular deaths are subclassified as myocardial infarction or stroke in some studies but not others. Certain studies report pneumonia as a pulmonary death, and others as an infection. Given these possibilities for differences, simply on the basis of different classification systems or sources of information, similarity in attributed causes of death in the different series is remarkable.

#### 4) Risk factors and predictive markers for mortality in RA

Predictive markers for mortality in patients with RA indicate unequivocally that mortality 5-15 years after baseline is predicted by almost all quantitative baseline measures indicating more severe clinical status. Mortality, therefore,

**Table IVa.** 1953-1984: Percentage of various acute attributed causes of death in rheumatoid arthritis.

	Cobb <i>et al.</i> 1953	Duthie <i>et al.</i> 1964	Uddin <i>et al.</i> 1970	Gordon <i>et al.</i> 1973	Isomaki <i>et al.</i> 1975	Monson and Hall 1976	Fleming <i>et al.</i> 1976	Lewis <i>et al.</i> 1980	Allebeck <i>et al.</i> 1981	Scott <i>et al.</i> 1983	Pincus <i>et al.</i> 1984	Prior <i>et al.</i> 1984	Vanden- broucke <i>et al.</i> 1984
Ref. no.	(1)	(3)	(4)	(12)	(13)	(20)	(21)	(23)	(25)	(28)	(30)	(34)	(37)
Specialized or Population study?	--	--	--	--	--	--	--	--	Population	--	--	--	--
Total no. of patients	583	307	475	127	1000	1035	102	311	293	112	75	448	209
Total no. of deaths	137	75	94	23	122	570	10	46	84	17	20	199	165
Source of data*	DC+MR	Unknown	DC+MR	MR	DC	Unknown	MR	DC	DC+MR	DC	DC+MR	DC	MR
Cardiovascular	33.8	41.3	54.3	13	46.7	54.5	30	41.3	54.8	35.3	40	39.2	43
Cancer	11.5	13.3	7.4	4.3	9	12.6	10	28.3	23.8	5.9	25	15.1	19.4
Renal	13.1	17.3	4.3	--	22.1	4.4	--	4.3	--	11.8	--	3	5.5
Respiratory	3.1	4	4.3	--	--	10	10	6.5	1.2	5.9	--	0.5	12.1
Infection	24.6	14.7	19.1	43.5	15.6	--	20	13	2.4	35.3	20	16.1	2.4
Gastrointestinal	6.2	8	2.1	--	--	4	--	4.3	6	--	--	5.5	5.5
Sudden death	--	--	--	--	--	--	--	--	--	--	--	--	--
Accidents or intoxication	--	0.5	--	--	0.8	--	--	--	--	--	--	--	0.6
Musculoskeletal diseases	--	--	--	--	--	6.7	20	--	4.8	5.9	--	17.1	10.3
Other	7.7	--	8.5	39.1	5.7	7.7	10	2.2	7	--	15	3.5	2.4

\*DC: death certificates; MR: medical records.

**Table IVb.** 1985-1998: Percentage of various acute attributed causes of death in rheumatoid arthritis.

	Mitchell <i>et al.</i> 1986	Erhardt <i>et al.</i> 1989	Saway <i>et al.</i> 1989	Lehtinen & Isomäki 1991	Jacobsson <i>et al.</i> 1993	Wolfe <i>et al.</i> 1994	Myllykangas- Luosujärvi <i>et al.</i> 1995	Jones <i>et al.</i> 1996	Wallberg- Jonsson <i>et al.</i> 1997	Soderlin <i>et al.</i> 1998	van den Borne <i>et al.</i> 1998		
Ref. no.	(38)	(42)	(43)	(45)	(47)	(48)	(55)	(56)	(63)	(64)	(65)		
Specialized or population study?	--	--	Focused	Focused	Population	--	Population	Focused	--	--	Focused		
Total no. of patients	805	107	113	573	172	3501	1666	518	604	606	103	208	415
Total no. of deaths	251	50	28	251	79	922	1186	193	201	265	22	16	57
Source of data*	DC+MR	DC	DC+MR	DC	DC	DC	DC	DC	DC+MR	DC	DC+MR		
Cardiovascular	42.6	40	25	16.9	25.3	47.1	50	49.7	49.2	53	45	25	38.6
Cancer	13.2	12	14.3	2.6	11.4	11.3	14	16.1	15.9	14	18	18.8	14
Renal	3.2	2	--	12.6	8.9	1.2	2.1	3.1	3	2	4.5	6.3	5.3
Respiratory	4.8	18	7.2	--	7.6	5	8	13	11.9	9	0	6.3	10.5
Infection	13.6	2	35.7	6.3	--	20.1	1.3	4.1	3.5	2	4.5	31.3	21.1
Gastrointestinal	6	4	3.6	--	7.6	5.7	4.4	4.1	4	6	4.5	--	1.8
Sudden death	--	--	--	--	--	--	--	--	--	--	--	--	--
Accidents or intoxication	4	--	--	--	10.1	2.6	3	--	--	--	9	6.3	--
Musculoskeletal diseases	10	20	--	--	--	1.3	12.1	3.6	4.5	9	14	--	--
Other	2.6	2	14.3	56.2	29.1	5.7	5.1	6.3	8	--	0	6.3	5.3

\*DC: death certificates; MR: medical records.

**Table IVc.** 1999-2001: Percentage of various acute attributed causes of death in rheumatoid arthritis.

	Lindqvist & Eberhardt 1999	Turesson 1999	Sokka 1999	Maiden 1999	Krause 2000	Kvalvik 2000	Kroot 2000	Riise 2001	Isaacs 2001	Martínez 2001	Uhrin 2001	Chevrel 2001	
Ref. no.	(66)	(67)	(68)	(70)	(72)	(73)	(74)	(75)	(77)	(79)	(81)	(82)	
Specialized or Population study?	--	--	--	--	Focused	--	--	--	--	--	Focused	--	
Total no. of patients	183	489	135	200	256	147	622	187	53	182	53	106	15
Total no. of deaths	18	119	25	95	88	68	55	91	13	23	25	45	11
Source of data*	DC	DC	DC+MR	DC+MR	MR	DC	MR	DC	DC	DC+MR	DC	DC	
Cardiovascular	50	52.9	40	42	28.4	42.6	47.3	38.5	46.2	21.7	28	30	54.5
Cancer	38.8	8.4	12	21	14.8	23.5	30.9	13.2	30.8	8.7	28	25	--
Renal	--	--	4	4	4.5	1.5	5.5	--	--	17.4	4	--	--
Respiratory	--	--	4	15	--	1.5	10.9	--	--	--	12	5	--
Infection	5.5	--	8	1.1	7.9	8.8	1.8	7.7	23.1	21.7	24	30	27.3
Gastrointestinal	--	--	8	5	8	--	--	--	--	4.3	--	5	--
Sudden death	--	--	--	--	--	2.9	--	3.3	--	--	--	--	--
Accidents or intoxication	5.5	--	8	2	--	--	--	4.4	--	4.3	--	--	--
Musculoskeletal diseases	--	--	4	5	--	16.7	--	--	--	--	--	--	--
Other	--	38.7	12	4	35.2	2.5	3.6	33.3	--	21.7	4	5	18.2

\*DCM: death certificates; MR: medical records.

**Table IVd.** 2002-2008: Percentage of various acute attributed causes of death in rheumatoid arthritis.

	Doran 2002	Bjornadal 2002	Mikuls 2002	Peltomaa 2002	Goodson 2002	Thomas 2003	Minaur 2004	Book 2005	Goodson 2005	Hakoda 2005	Carmona 2007	Young 2007	Mattey 2007	Nikolaisen 2008	
Ref. no.	(83)	(92)	(93)	(94)	(95)	(101)	(11)	(111)	(112)	(113)	(116)	(121)	(122)	(124)	
Specialized or Population study?	Populat- ion	Populat- ion	Populat- ion	--	--	Populat- ion	--	--	Focused	--	--	Focused	Focused	Focused	
Total no. of patients	609	46917	158	150	575	20875	100	152	1010	91	789	789	1429	767	111
Total no. of deaths	334	25353	30	24	84	158	84	111	470	83	20	75	459	186	20
Source of data*	DC	DC	DC	DC+MR	DC	DC	MR	DC	DC	DC	DC	DC	DC	DC	MR
Cardiovascular	46.8	50.6	32	41.7	38.1	45.2	45.2	45.9	46.8	34.9	35	22.7	41	37.1	20
Cancer	10.3	12	28.6	33.3	32	14.3	14.3	8.1	18.7	14.5	15	17.3	24	24.7	5
Renal	--	3.2	--	--	--	2.8	2.8	--	--	2.4	--	--	2	2.2	--
Respiratory	10	4.2	--	8.3	11.9	15.7	15.7	--	16.4	15.7	--	--	22	13.4	--
Infection	15.2	7.4	7.1	12.5	--	1.1	1.1	18.9	--	4.8	35	18.7	5	15.6	20
Gastrointestinal	--	5.6	--	--	--	5.4	5.4	--	--	6	--	--	3	4.3	--
Sudden death	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Accidents or intoxication	--	2.4	--	--	--	--	--	--	--	--	--	--	--	--	--
Musculoskeletal diseases	--	11	--	4.2	--	8.8	8.8	--	--	--	--	--	--	--	--
Other	17.6	3.6	32.1	--	18	6.3	6.3	26.1	18.1	21.7	--	18.7	3	2.7	55

\*DC: death certificates; MR: medical records.

**Table V.** Summary of causes of death – Percentages of death due to various causes according to period and type of study.

	1953-1989	1990-2000	2001-2008	Specialized studies	Population studies	Total*	U.S. Averages 1977	U.S. Averages 2005
No. of reports (cohorts)	14 (14)	9 (9)	10 (11)	10 (13)	7 (7)	50 (54)	--	--
Total no. of patients	5696	5986	3083	6163	70690	91618	--	--
Total no. of deaths	1779	1589	619	2039	27224	33250	--	--
Cardiovascular	39.6	46.7	38.6	33.5	43.5	39.6	41.0	38.3 <sup>†</sup>
Cancer	13.4	19.8	18.7	17.1	16.3	16.8	20.4	22.8
Renal	8.3	3.2	7.5	4.8	4.3	5.8	1.1	1.8
Respiratory	7.2	6.5	12.9	11.8	7.8	9.0	3.9	5.3
Infection	18.5	6.5	17.1	17.0	5.8	14.3	1.0	4.4
Gastrointestinal	5.1	5.8	5.2	4.2	5.8	5.1	2.4	1.1
Sudden Death	--	2.9	3.3	0.0	--	3.1	--	--
Accidents or intoxication	1.5	5.4	4.4	6.3	5.2	4.2	5.4	6.9
RA/Musculoskeletal diseases	12.9	8.3	6.5	4.1	9.2	9.4	--	--
Other	8.9	9.5	20.5	13.0	14.4	12.9	24.8	21.4

\* The total of these percentages exceeds 100%, as each value is based on the mean of percentage of deaths attributed to each cause in each of the 50 reports, so as to weight all studies equally, rather than to weight studies according to the number of included patients.

<sup>†</sup> includes cerebrovascular and diabetes.

US averages 1977 from Vital statistics of the United States 1977 (127).

US averages 2005 from CDC/NCHS National Vital Statistics System ([http://www.cdc.gov/nchs/data/dvs/LCWK9\\_2005.pdf](http://www.cdc.gov/nchs/data/dvs/LCWK9_2005.pdf)).

is not simply a random event in people with RA, and secondary to drug toxicities in only 2% of patients.

Predictive markers for mortality were reported for 53 of the 84 cohorts, and may be classified in 4 categories: *a) non-modifiable variables*, including demographic variables (age, sex, socioeconomic status), duration of disease, and major histocompatibility and other genes; *b) traditional clinical measures*, including joint counts, radiographs, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor and disease activity score (DAS); *c) modifiable functional and global measures*, including physical functional assessed by performance measures, physical function assessed by patient questionnaires, physician global estimate of status, and patient global estimate of status; *d) other potentially modifiable measures* not specific to RA but important for outcomes, including extra-articular disease, comorbidities, pain, psychological status, and body mass index.

The observation that poor clinical status according to all these variables predicts a higher risk of mortality may be viewed as essentially confirming a rather trivial truism: that people who have more severe illness are more likely to

die. At the same time, description of “severe illness” according to quantitative measures rather than clinical impressions would appear a real advance to better estimate mortality risk, and determine whether improvements in these measures toward normal values are associated with improved long-term survival. Furthermore, long-term observational studies could be performed to recognize possible target values for prognostic variables, which may not require complete remission toward favorable mortality outcomes.

Analyses of predictive markers for premature mortality in RA in various reports are described according to the number of reports in which each is included. Obviously, it is not possible to assess a measure as a possible risk factor for mortality if baseline data concerning the variable are not available or reported. The estimates presented may not be entirely accurate, as certain variables might not have been reported, either because they were presumed significant in the prognosis of mortality (*e.g.*, age, male sex) or as they were found not significant in the prognosis of mortality. Nevertheless, a “best effort” to compile available data appears informative.

Possible risk factors for premature mortality in RA are further classified into 5 categories (Table VI): reported as not statistically significant (although poorer status usually indicated a greater risk for mortality); statistically significant only in univariate analyses, without report of multivariate analyses, generally prior to 1985-1990; statistically significant only in univariate analyses, but not significant in multivariate analyses which include other possible predictive markers in addition to age and sex; statistically significant in both univariate and multivariate analyses that did not include a functional status questionnaire; statistically significant in both univariate and multivariate analyses that included a functional status questionnaire. The rationale for these categories of statistical significance includes that multivariate analyses of mortality in RA were not reported until the mid-1980s (31, 32, 38, 41), so it is not possible to assess whether variables might be significant in such analyses in earlier reports. Furthermore, the highest level of significance in the prognosis of mortality in RA in most studies is physical function on a patient questionnaire (Fig. 2); therefore, studies were classified regarding whether or not a measure of physical function was included.



### **Non-modifiable risk factors for mortality**

**Age.** Age was a statistically significant predictor of mortality in all 33 cohorts in which it was reported, including in 27 multivariate analyses, 15 of which included a functional status questionnaire (Table VI). As noted above, absolute mortality rates are almost invariably greater in older people, whereas relative mortality rates are generally greater in younger people.

**Sex.** Male sex was a significant predictor of mortality in 27 of 30 studies, including 19 multivariate analyses, 10 of which included a functional status questionnaire (Table VI). The absolute and relative mortality rates differ in two groups – absolute mortality rates are higher in males, but relative mortality rates are higher in females, in whom absolute mortality rates in the general population are lower than in males.

**Socioeconomic status.** A measure of socioeconomic status was included in 13 reports as a possible predictor of mortality, primarily formal education level in the U.S. and the Carstairs index of social deprivation in the U.K. (204). In 10 of these analyses, socioeconomic status was a significant predictor of mortality in univariate analyses, including 4 in which this measure was also significant in multivariate analyses that included a functional status questionnaire (Table VI) (Fig. 2). These data suggest that an indicator of socioeconomic status might be included in all long-term databases to better characterize prediction of mortality and other clinical outcomes in RA. Socioeconomic status is an important indicator of clinical status, not only in RA and other rheumatic diseases (189), but also in most diseases, as discussed elsewhere in this Supplement (205).

**Duration of disease.** Duration of disease was a significant predictor of mortality in 9 of 21 reports, including only 1 in multivariate analyses (107) (Table VI). In many reports, the prognostic significance of duration of disease for mortality is explained by age, since individuals with longer duration tend to be older. These findings are consistent with different rates of disease progression in different individual patients, as

duration of disease is often correlated only weakly with measures of clinical status, other than radiographic scores, which present cumulative, irreversible damage (206).

**Major histocompatibility locus – shared epitope.** The major histocompatibility locus was analyzed as a possible predictor of mortality in 5 cohorts, and indicated a significantly higher risk of mortality in 3 reports, one in univariate analysis where multivariate analysis was not reported (120), one in univariate but not multivariate analyses (122), and one in both univariate and multivariate analyses (97) (Table VI). In one report, there was not a significant increase in mortality in the entire cohort compared to the general population (74). In a second cohort, HLA DR4 was not a significant predictor of mortality, though HLA B27, curiously, predicted both cardiovascular events and mortality (71).

Gonzalez-Gay (120) found increased risk of cardiovascular mortality according to the HLA shared epitopes 04 and 0404; 0404 was also prognostic of increased cardiovascular events. Information concerning overall mortality in the cohort from causes other than cardiovascular disease was not presented. In multivariate analyses, CRP and ESR also were significant, but not rheumatoid factor. These regressions did not include any of the other Core Data Set measures based on a joint count or patient questionnaire.

In the Norfolk Arthritis Register (NOAR) early arthritis cohort, significant risk of mortality was seen in individuals with 2 copies of the shared epitope alleles, particularly 0101/0401, compared to individuals with one copy or no copies of the shared epitope alleles. Again, rheumatoid factor was found to add to the risk in individuals who did not have shared epitope, but not anti-CCP (97).

In 767 patients in the Early RA Study (ERAS) cohort recruited in 1987, the genotypes 0101/0401 and 0404/0404, which were found in 37 (4.8%) and 10 (1.3%) of 767 patients in the entire cohort, were significant predictors of ischemic heart disease (122). HLA DR4 was not predictive of mortality for the

entire cohort, but the higher risk of mortality from ischemic heart disease is similar to 2 of the other studies (97, 120).

HLA DR4 may serve as a marker for progressive RA versus self-limited polyarthritis in inception cohorts. Early studies indicated that HLA haplotype, rheumatoid factor, ESR, and radiographic changes were associated with one another at higher levels than with joint count or patient questionnaire measures (207), and similar associations have been described in many studies (208, 209) (Fig. 3). Although this cluster of measures may appear the more substantial measures in RA, including for the prognosis of mortality, the patient questionnaire measures generally have greater significance to predict mortality. Nonetheless, these studies may provide important long-term clues concerning mechanisms of cardiovascular comorbidity and mortality in patients with RA.

### **Traditional measures of RA clinical status as predictors of mortality**

**Joint count.** Swollen and tender joint counts were reported in 18 cohorts, and were statistically significant in the prediction of mortality in 9 (50%) (Table VI) (Fig. 2), including 5 (38%) in univariate analyses only (without multivariate analyses), and 4 (22%) in multivariate analyses, 3 of which included a functional status questionnaire. In 2 additional studies (61, 100), the swollen and tender joint count were not significant in prediction of mortality, while joint count data concerning deformity or limited motion were significant in univariate but not multivariate analyses. These data suggest that it may be desirable for long-term longitudinal analyses to assess joints at baseline not only for tenderness and swelling, but also for deformity or limited motion (210). A swollen and tender joint count may not be sufficient for long-term studies, as swollen joints may improve over 5-6 years, while joint deformity and radiographic changes may progress (211). One study suggested that large joints appeared far more significant in the prognosis of mortality than small joints, and a reduced “joint count” including only 6 joints – shoulders, hips and knees – was as informative to identify the likelihood

**Table VI.** Numbers of possible predictive markers of mortality classified into 5 categories according to non-significance and significance in univariate and multivariate analyses.

Variable, number of studies that report this variable	Not Significant	Significant in univariate analysis		Significant in univariate and multivariate analyses	
		No multivariate analysis available	NOT significant in multivariate analysis	No functional status questionnaires	Functional status questionnaires INCLUDED
Age, 33	0	5 (36;45;64;79;113)	1 (55)	12 (38;42;47;48;63;66; 68;69;71;74;76;85)	15 (33;41;46;58;61;70; 90;94;95;100;102; 105;109;121;123)
Sex, 30	3 (6;80;113)	4 (14;25;36;79),	4 (33;55;68;100)	9 (38;47;48;63;66; 71; 74;81;85)	10 (41;46;58;90;94;102; 105;109;121;123)
Disease duration, 21	12 (33;38; 47;58;64;75; 87;90;94;94;109;118)	2 (36;45)	6 (41;46;48;61;100;111)	0	1 (107)
Major Histocompatibility Locus, 5	2 (71;74)	1 (120)	1 (122)	1 (97)	0
Socioeconomic Status, 13	3 (44;46;64)	0	6 (61;68;70;71;90;100)	0	4 (33;48;58;121)
Swollen and Tender Joint Count, 18	9 (10;61; 62;64;66;76; 80;100;121)	0	5 (33;42;46;102;111)	1 (38)	3 (48;94;105)
Deformity or Limited Motion Joint Count, 2	0	0	2 (61;100)	0	0
Radiographs, 18	7 (22;32;38; 61;64; 66; 120)	1 (3)	8 (48;76;80;87;94; 111; 113;121)	1 (55)	1 (102)
ESR, 19	6 (10;42;64; 66;76;80)	2 (3;120)	4 (61;94;113;123)	4 (71;87;111;114)	3 (48;102;121)
Rheumatoid Factor, 29	10 (10;61;64; 66;75; 94; 100;110-112)	2 (25;45)	4 (68;74;113;121)	8 (38;47;55;69;76; 80; 85;93)	5 (48;95;102;106;109)
DAS, 3	0	0	2 (76;121)	0	1 (96)
Function: Physical Measure, 6	0	1 (64)	5 (33;48;61;102;121)	0	0
Function: Questionnaire, 18	1 (95)	1 (64)	3 (70;94;100)	NA	13 (32;41;46;48;58;61; 90;96;102;105; 109; 118;121)
MD Global, 10	0	4 (3;6;22;25)	3 (61;100;121)	2 (38;111)	1(48)
Patient Global, 6	0	0	3 (46;61;111)	2 (43;44)	1 (118)
Extra-articular Disease, 18	3 (6;22;120)	3 (12;29;64)	4 (38;94;107;121)	5 (42;43;76;87;123)	3 (48;95;102)
Co-morbidities, 23	1 (46)	3 (19;44;64)	4 (33;38;94;111)	8 (47;63;69;71;87; 93; 100;114)	7 (48;61;90;107;109; 118;121)
Pain, 6	4 (44;61;76; 90)	0	1 (46)	0	1 (118)
Psychological Status, 5	2 (44;61)	0	1 (113)	0	2 (58;102)
Body Mass Index, 2	0	0	2 (86;114)	0	0
Glucorticoids, 11	2 (26;118)	2 (22;46)	3 (105;111;121)	2 (71;84)	2 (31;48)

of mortality as a complete joint count (33).

**Radiographs.** Radiographs were significant predictors of mortality in 11 (61%) of 18 reported cohorts, including 9 in univariate analysis and 2 in multivariate analyses, one of which included a patient questionnaire (102) (Table VI) (Fig. 2). This was a large

study of 1387 patients from the Wichita Arthritis Center, illustrating that most available baseline indicators of severe disease status are significant predictors of mortality in univariate as well as multivariate analyses in large databases, but not in smaller databases. All published analyses of radiographs in the prediction of mortality are based on

hand joints, which explain in part the lower significance than other variables, including physical function questionnaires, in the prognosis of mortality.


**Erythrocyte sedimentation rate.** ESR was a significant predictor of mortality in 13 (68%) of 19 reported cohorts, including 7 in multivariate analyses, 3 of which also included a functional status

questionnaire (Table VI) (Fig. 2). This finding may reflect the fact that ESR has been found to be normal at presentation in 40% of patients with RA (174). Furthermore, a similar proportion of patients with normal or abnormal ESR were treated with methotrexate or biological agents (Sokka and Pincus, unpublished data). A high ESR may identify patients with a likelihood of progressive RA versus self-limited inflammatory polyarthritis in inception cohorts.

**Rheumatoid factor.** Rheumatoid factor was a significant predictor of mortality in 19 (66%) of 29 reported cohorts, 6 in univariate analysis only, and 13 in multivariate analyses, 5 of which also included a functional status questionnaire (Table VI) (Fig. 2). These 5 cohorts included 2 very large databases (48, 102), and 2 inception cohorts (95, 109) in which rheumatoid factor may serve to identify a higher likelihood of progressive RA versus self-limited polyarthritis.


The relatively limited significance of rheumatoid factor as a predictor of mortality may be unexpected by most rheumatologists, as textbooks have emphasized for many years that seropositive individuals have more severe disease than individuals who are not seropositive. Rheumatoid factor does serve as a marker for progressive RA versus self-limited inflammatory polyarthritis which may even meet classification criteria for RA, as discussed above, and may be a more significant predictor in inception cohorts versus cohorts of established patients. As noted above, HLA haplotype, rheumatoid factor, ESR, CRP and radiographs tend to be associated with one another more than with patient and joint count measures (Fig. 3), while the latter measures tend to be more significant predictors of mortality (207).

**Disease activity score (DAS).** A DAS28 was included in only 3 cohorts, all after 2000, and was a significant predictor of mortality in univariate but not multivariate analyses in 2 reports, and significant in multivariate analysis that included a functional status questionnaire in 1 report (96) (Table VI). This was an inception cohort in which DAS28 may



**Fig. 2.** Significance of 8 variables as possible predictors of mortality. Bars indicate, for each variable, percentage of reports that included the variable in which it was significant in multivariate analyses (black), significant in univariate analyses (gray), or not significant (white).

## Two types of measures to assess RA



**Fig. 3.** Two types of measures to assess RA. Almost all measures are correlated significantly in most cohorts. ESR, CRP, rheumatoid factor, anti-CCP and shared epitope in the left circle are correlated at higher levels with one another and with radiographic changes, joint deformity and duration of disease than with swollen joint count, and at even lower levels with measures in the right circle. Measures in the right circle are correlated with one another at higher levels than with swollen joint count, and at even lower levels with measures in the left circle. The left cluster of measures is more important in pathogenesis of RA, while physical function on a patient questionnaire generally has greater significance to predict severe outcomes, including work disability and mortality.

also have served in part as a marker of progressive rather than self-limited disease (96).

**Physical function and global measures**  
*Physical function assessed by performance measures.* A measure of physical performance was a significant predictor of mortality in univariate analyses in all 6 reported cohorts, but not significant in any multivariate analyses (Table VI). Specific cutpoints for physical measures of grip strength, walking time and button test were identified to recognize

levels of survival over 5, 10 or 15 years (33). The rheumatology community has largely abandoned the use of these measures in clinical research and clinical care, possibly because of a perception that they are poorly reliable. However, they may be quite reliable when performed according to a standard protocol (212, 213). Furthermore, these measures overcome cultural limitations of patient questionnaires.

*Physician global estimate of status.* Physician global estimate of status was recognized initially in 1981 by Rasker

and Cosh as a predictor of mortality (6), and was significant in all 10 cohorts reported, 7 in univariate analyses, 4 of which had no available multivariate analyses, and in 3 multivariate analyses, one of which included a functional status questionnaire. American Rheumatism Association (ARA) functional class, the primary physician global estimate reported prior to 2000, measured one year after baseline, had greater significance in the prediction of mortality than the baseline value (6).

*Patient global estimate of status.* Patient global estimate of status was a significant predictor of mortality in all 6 cohorts in which it was reported, including 3 in univariate analyses only, and 3 in multivariate analyses, one of which included a functional status questionnaire. These data indicate that global measures are quite robust, as these measures also were the most significant of all RA Core Data Set measures (153) to distinguish active from placebo treatment in several randomized controlled clinical trials (214, 215).

*Physical function assessed by patient questionnaires.* A functional status questionnaire, generally a health assessment questionnaire (HAQ) or multidimensional HAQ (MDHAQ), was a significant predictor of mortality in 17 of 18 reports, including 4 in univariate analyses only (1 with no available multivariate analyses and 3 which included multivariate analyses) and 13 in multivariate analyses (Table VI) (Fig. 2). The one study in which a functional status questionnaire was not a significant predictor (95) was an inception cohort in which rheumatoid factor had the highest level of significance to predict mortality, possibly in part as a marker to identify individuals with progressive RA versus self-limited disease.

Several reports have documented that patient HAQ score at 1 year is substantially more prognostic of mortality than the baseline HAQ (96, 121), similar to observations of global status estimates. It is possible that similar observations might be seen for swollen joints, ESR, or other modifiable measures of clinical status. The data indicate the value of ongoing periodic quantitative assessment of patient status.

#### **Other variables that may be significant in the prognosis of mortality**

*Extra-articular disease.* Extra-articular disease was reported as a significant predictor of mortality in 15 (83%) of 18 cohorts (Table VI) (Fig. 2), including 7 in univariate analyses, 3 of which did not include multivariate analyses, 4 in which it was not significant in multivariate analyses, and 8 in multivariate analyses, 3 of which included functional status questionnaires. Extra-articular disease provides an important marker for severity of RA.

*Comorbidities.* Comorbidities were significant in 22 of 23 cohorts in which a comorbidity variable was reported (Table VI) (Fig. 2), 7 in univariate analyses, 3 of which did not have multivariate analyses available, and 15 in multivariate analyses, 7 of which included a functional status questionnaire. Comorbidities appear comparable to functional status and global measures as highly significant predictors of mortality in patients with RA.

*Pain.* Pain was included in 6 cohorts, and curiously was a significant predictor of mortality in only 2 studies, including one in univariate but not multivariate analysis (46), and one in multivariate analysis, which included a functional status questionnaire (118) (Table VI). In one report, patients who died had somewhat lower, not significant, pain scores than those who survived (61). A pain score appears far less prognostic of mortality than a physical function score, possibly reflecting patients with RA and concomitant fibromyalgia, seen in 20-30% of RA patients (216).

*Body mass index.* Two recent reports (86, 114) indicate a very interesting observation that a low body mass index was curiously found to be a significant risk factor for mortality in RA patients, unlike in the general population. This observation may be interpreted that cachexia serves as a marker of severe RA.

*TNF receptors.* In a cohort of 401 patients with RA seen initially between 1993 and 1998 at Staffordshire, England, circulating levels of tumor necrosis factor (TNF) receptors predicted mortality significantly (123). The soluble TNF receptor 1 was a significant predictor

of mortality in multivariate analyses adjusted for age, sex, disease duration, ESR, CRP, rheumatoid factor, nodules, MHAQ score, and smoking. These data may be interpreted to suggest that anti-TNF therapies may reduce overall mortality in RA, as documented in recent reports presented below.

*Complexities in analyses.* Complexities in analyses of risk factors for premature mortality (Table VII) include:

- a) *Only variables that are included can be analyzed.* It is axiomatic that variables that are not available cannot be analyzed as potential risk factors for premature mortality. For example, if a patient questionnaire score for physical function or marker of socioeconomic status is not included in a baseline database, it could not be assessed as a possible independent variable in mortality outcomes. The available data suggest that the four most important variables for prediction of mortality are age, sex, comorbidities, and functional status, all of which should be included in long-term longitudinal databases to analyze mortality in RA.
- b) *Absolute risk versus relative risk may differ substantially.* As noted above, the absolute risk of mortality is greater for males and older individuals, but the relative risk is higher for females in younger individuals. Therefore, different reports might suggest that males versus females or younger versus older people might have better or worse outcomes without specifying how these outcomes are defined.

### **5) Therapies and mortality in RA**

*Nonsteroidal anti-inflammatory drugs (NSAIDs).* Among 1666 Finnish patients with RA who died in 1989, NSAIDs contributed to 30 deaths (1.8%), while disease-modifying antirheumatic drugs (DMARDs) contributed to only 6 deaths (0.3%) (217). Therefore, more severe disease was the primary basis for premature mortality over the subsequent 5-20 years, but treatments did account for 2% of deaths.

*Glucocorticoids.* Glucocorticoids have been reported as a predictor of mortality in 9 (82%) of 11 cohorts, including

2 in univariate analyses with no available multivariate analyses (22, 46), 3 in univariate but not multivariate analyses (105, 111, 121), and 4 in multivariate analyses (31, 48, 71, 84), 2 of which included functional status questionnaires (31, 48). There is relatively little information concerning the dose of glucocorticoids, and one interpretation of the data is that glucocorticoid use is a marker for more severe clinical status. In one study (71), early glucocorticoid treatment was a significant predictor of mortality in multivariate analyses, while long-term treatment was associated with reduced risk of mortality. Most of the glucocorticoid use prior to the mid-1990s regarded “low-dose” as 10 mg/day, whereas at this time many suggest that low-dose involves 5 mg/day or even less with relatively little toxicity (218-220).

**Gold salts.** Lehtinen and Isomaki reported improvement in mortality outcomes associated with the use of therapeutic gold salts in 1991 (45), echoing previous observations indicating that morbidity, including radiographic progression, was favorably affected by intramuscular gold salts (221). Although gold salts have been supplanted largely by methotrexate, sulfasalazine, hydroxychloroquine, and biologic agents, this study established a principle that control of inflammation by any agent might be associated with better mortality outcomes.

**Methotrexate.** Krause, Herborn, Rau and colleagues (72) reported in 2000 that patients who responded to methotrexate had substantially lower mortality than patients who did not respond to methotrexate. Choi, Wolfe and colleagues (91) reported in 2002 that methotrexate treatment results in improved survival for patients with RA, based on a sophisticated statistical model that adjusted for confounding by indication, *i.e.*, that patients with more severe disease were more likely to receive methotrexate. As noted, long-term clinical trials cannot be performed in patients with RA (199), and those data are encouraging that reduction of premature mortality in RA is possible.

**Biologic agents.** Carmona *et al.* reported a standard mortality ratio of 0.32 in

**Table VII.** LIMITATIONS: Complexities in the analysis of mortality in rheumatoid arthritis (and possibly other rheumatic diseases).

- 
1. Mortality rates
    - a) No “gold standard” for diagnosis.
    - b) Self-limited early inflammatory arthritis included in early RA cohorts.
    - c) Patient characteristics vary considerably in different cohorts.
    - d) Different reference mortality rates.
    - e) Changing natural history of RA.
    - f) Period of observation.
    - g) Limited resources for study.
    - h) Absence of long-term clinical trials.
    - i) Numbers used to describe risk.
  2. Causes of death
    - a) Source of information – death certificate or medical record.
    - b) Underestimation of RA as associated with premature mortality.
    - c) Differences in reporting in different series.
  3. Markers for premature mortality
    - a) Only variables that are included can be analyzed.
    - b) Absolute risk versus relative risk may differ substantially.
  4. Possible favorable benefits of therapies on mortality rates
    - a) No long-term randomized controlled clinical trials.
    - b) Mortality is a “lagging indicator”.
    - c) Similarity of disease effects and adverse events.
- 

4,459 patients treated with anti-TNF agents in Spain compared to a control cohort of 789 RA patients (116). SMR were 0.58 for cardiovascular events, 0.52 for infection, and 0.36 for cancer-related deaths – although confidence intervals crossed one, due to small numbers of patients. The authors concluded that morbidity (other than infection) and mortality (including infection) were lower in patients treated with anti-TNF antagonists than in a standard observational cohort of RA patients. Jacobsson *et al.* (118) reported a hazard ratio for mortality of 0.65 for patients treated with anti-TNF agents, compared to those not treated, adjusted for age, sex, disability and baseline comorbidity, significant in women but not in men. Taken together, these reports suggest improved mortality outcomes associated with anti-TNF therapies, but require confirmation in other sites over longer periods.

**Complexities in analyses.** Complexities in analyses of therapies in premature mortality of RA (Table VII) include:

- a) *No long-term randomized controlled clinical trials.* As discussed above, it is not possible to conduct long-term randomized controlled clinical trials in symptomatic diseases such as RA. Reliance on long-term databases is always affected by “confounding by indication,” *i.e.*, patients with more severe disease

are more likely to be treated more aggressively, leaving greater risks of therapies. For example, associations of higher mortality rates with glucocorticoids may be explained in part by glucocorticoids being a marker for more severe disease.

- b) *Mortality is a “lagging indicator.”* Mortality outcomes are seen at least 3-10 years after baseline. Therefore, a study of mortality at this time may include many patients treated prior to the biological era. Studies focused only on patients who receive biological therapy suggest better mortality outcomes, but longer observations are needed. Possible advances may require years for documentation.

- c) *Similarity of disease effects and adverse events.* Infections are increased significantly in people with RA, but also may be a serious adverse event of therapy with biological agents. Therefore, a higher level of infection in people treated with biological agents might reflect higher disease severity and/or an adverse event associated with the therapy. Without a randomized trial it may be difficult to sort this out. Higher mortality rates from infection in people who take biological therapies may nonetheless be lower than expected in people with severe disease.

## Conclusions

Analysis of mortality in RA over the past 60 years has provided considerable impetus to recognition of RA as a serious chronic disease. Certain complexities, including the absence of a "gold standard" for diagnosis, patient heterogeneity, and limited resources, have complicated analyses of mortality. The causes of death overall are similar to those in the general population, with earlier cardiovascular disease and a higher level of infection, pulmonary, gastrointestinal and renal disease. Increased mortality rates can be recognized only with long-term longitudinal data for comparison with the general population. All clinical markers that indicate more severe clinical status are associated with a higher risk of death. The highest levels of prognostic significance are seen for higher age, male sex, poorer functional status, and comorbidities. Several reports suggest improved mortality outcomes associated with effective therapies, but these remain to be confirmed in longitudinal analyses.

In a presidential address to the U.K. Royal College of Physicians in 1963 (2), Reah commented on his earlier impression of RA as a mild disease: "I now believe that my earlier impression was based on patients, certainly impressive when we see them, who do remain otherwise well for many years .... Those who develop other disorders or become more or less completely incapacitated no longer come to our clinics and they are thus forgotten unless we keep in touch with them...I cannot now fully agree with the folk lore of America nor with the opinion that rheumatism is a good healthy complaint. It may be, however, that from the study of groups of patients for many years and observations on the natural history of the disease, with its remissions and exacerbations, inevitably modified by therapy, there may yet be derived knowledge of its causation and its more effective treatment."

Dr. Reah's recognition of comorbidities and poor function as primary predictors of mortality, and his hope that longitudinal data will lead to improved outcomes, remain as valid today as 45 years ago. Further research might focus

more on target values associated with a favorable prognosis, rather than regressions to determine the statistical significance of a variable in the prognosis of mortality. In clinical settings, it might be considerably more informative to know whether a specific number of swollen joints, or a specific HAQ or MDHAQ score, might be associated with similar levels of survival as no swollen joints, or HAQ or MDHAQ scores of 0, or that DAS28 levels of 3.2, CDAI levels of 10, or RAPID3 levels of 2 (on a 0-10 scale), might be associated with mortality outcomes comparable to entirely normal values. Such data would provide clinicians with targets for therapy based on prevention of mortality.

All rheumatology sites are encouraged to develop clinical databases, remembering that a clinical tool which calculates and records disease activity variables only, or an electronic medical record with lengthy texts but no option to analyze collected material, is not a database for long-term longitudinal observations. A database is required to analyze mortality outcomes, causes of death, comparison with the general population, and risk factors for mortality. Further studies of these matters should lead to improved outcomes for people with RA.

## Acknowledgments

We thank Chelsey Forbess for help in compiling the tables, Ann Rupel for expert preparation of the manuscript and figures, and many colleagues for help with the tables and comments on analyses of their cohorts, particularly Drs. Hilal Maradit Kremers, Johannes Rasker, and Frederick Wolfe.

## References

1. COBB S, ANDERSON F, BAUER W: Length of life and cause of death in rheumatoid arthritis. *N Engl J Med* 1953; 249: 553-6.
2. REAH TG: The prognosis of rheumatoid arthritis (185 patients followed up over 13 years). *Proc R Soc Med* 1963; 56: 813-7.
3. DUTHIE JJR, BROWN PE, TRUELOVE LH, BARAGAR FD, LAWRIE AJ: Course and prognosis in rheumatoid arthritis: a further report. *Ann Rheum Dis* 1964; 23: 193-204.
4. UDDIN J, KRAUS AS, KELLY HG: Survivorship and death in rheumatoid arthritis. *Arthritis Rheum* 1970; 13: 125-30.
5. JACOBY RK, JAYSON MIV, COSH JA: Onset, early stages, and prognosis of rheumatoid

- arthritis: a clinical study of 100 patients with 11-year follow-up. *Br Med J* 1973; 2: 96-100.
6. RASKER JJ, COSH JA: Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. *Ann Rheum Dis* 1981; 40: 115-20.
7. COSH JA, RASKER JJ: A 20-year follow-up of 100 patients with rheumatoid arthritis (RA). *Ann Rheum Dis* 1982; 41: 317.
8. RASKER JJ, COSH JA: The natural history of rheumatoid arthritis: a fifteen year follow-up study. The prognostic significance of features noted in the first year. *Clin Rheumatol* 1984; 3: 11-20.
9. RASKER JJ, COSH JA: The natural history of rheumatoid arthritis over 20 years. Clinical symptoms, radiological signs, treatment, mortality and prognostic significance of early features. *Clin Rheumatol* 1987; 6 (Suppl. 2): 5-11.
10. REILLY PA, COSH JA, MADDISON PJ, RASKER JJ, SILMAN AJ: Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. *Ann Rheum Dis* 1990; 49: 363-9.
11. MINAUR NJ, JACOBY RK, COSH JA, TAYLOR G, RASKER JJ: Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. *J Rheumatol* 2004; 31(S69): 3-8.
12. GORDON DA, STEIN JL, BRODER I: The extra-articular features of rheumatoid arthritis: a systematic analysis of 127 cases. *Am J Med* 1973; 54: 445-52.
13. ISOMÄKI HA, MUTRU O, KOOTA K: Death rate and causes of death in patients with rheumatoid arthritis. *Scand J Rheumatol* 1975; 4: 205-8.
14. KOOTA K, ISOMÄKI H, MUTRU O: Death rate and causes of death in RA patients during a period of five years. *Scand J Rheumatol* 1977; 6: 241-4.
15. MUTRU O, LAAKSO M, ISOMÄKI H, KOOTA K: Ten year mortality and causes of death in patients with rheumatoid arthritis. *Br Med J* 1985; 290: 1797-99.
16. LAAKSO M, MUTRU O, ISOMÄKI H, KOOTA K: Cancer mortality in patients with rheumatoid arthritis. *J Rheumatol* 1986; 13: 522-6.
17. LAAKSO M, ISOMÄKI HA, MUTRU O, KOOTA K: Death certificate and mortality in rheumatoid arthritis. *Scand J Rheumatol* 1986; 15: 129-33.
18. LAAKSO M, MUTRU O, ISOMAKI H, KOOTA K: Mortality from amyloidosis and renal diseases in patients with rheumatoid arthritis. *Ann Rheum Dis* 1986; 45: 663-7.
19. MUTRU O, LAAKSO M, ISOMÄKI H, KOOTA K: Cardiovascular mortality in patients with rheumatoid arthritis. *Cardiology* 1989; 76: 71-7.
20. MONSON RR, HALL AP: Mortality among arthritics. *J Chron Dis* 1976; 29: 459-67.
21. FLEMING A, CROWN JM, CORBETT M: Prognostic value of early features in rheumatoid disease. *Br Med J* 1976; 1: 1243-5.
22. CORBETT M, DALTON S, YOUNG A, SILMAN A, SHIPLEY M: Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. *Br J Rheumatol* 1993; 32: 717-23.

23. LEWIS P, HAZLEMAN BL, HANKA R, ROBERTS S: Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. *Ann Rheum Dis* 1980; 39: 457-61.
24. LINOS A, WORTHINGTON JW, O'FALLON WM, KURLAND LT: The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. *Am J Epidemiol* 1980; 111: 87-98.
25. ALLEBECK P, AHLBOM A, ALLANDER E: Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate: eleven year follow-up of an epidemiological study. *Scand J Rheumatol* 1981; 10: 301-6.
26. ALLEBECK P, RODVALL Y, ALLANDER E: Mortality in rheumatoid arthritis, particularly as regards drug use. *Scand J Rheumatol* 1985; 14: 102-8.
27. ALLEBECK P: Increased mortality in rheumatoid arthritis. *Scand J Rheumatol* 1982; 11: 81-6.
28. SCOTT DL, COULTON BL, CHAPMAN JH, BACON PA, POPERT AJ: The long-term effects of treating rheumatoid arthritis. *J R Coll Physicians Lond* 1983; 17: 79-85.
29. FOSTER CS, FORSTOT SL, WILSON LA: Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. *Ophthalmology* 1984; 91: 1253-63.
30. PINCUS T, CALLAHAN LF, SALE WG, BROOKS AL, PAYNE LE, VAUGHN WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. *Arthritis Rheum* 1984; 27: 864-72.
31. PINCUS T, CALLAHAN LF: Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. *J Chronic Dis* 1985; 38: 973-84.
32. PINCUS T, CALLAHAN LF, VAUGHN WK: Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. *J Rheumatol* 1987; 14: 240-51.
33. PINCUS T, BROOKS RH, CALLAHAN LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. *Ann Intern Med* 1994; 120: 26-34.
34. PRIOR P, SYMMONS DPM, SCOTT DL, BROWN R, HAWKINS CF: Cause of death in rheumatoid arthritis. *Br J Rheumatol* 1984; 23: 92-9.
35. SYMMONS DPM, PRIOR P, SCOTT DL, BROWN R, HAWKINS CF: Factors influencing mortality in rheumatoid arthritis. *J Chronic Dis* 1986; 39: 137-45.
36. SYMMONS DP, JONES MA, SCOTT DL, PRIOR P: Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. *J Rheumatol* 1998; 25: 1072-7.
37. VANDENBROUCKE JP, HAZEVOET HM, CATS A: Survival and cause of death in rheumatoid arthritis: A 25-year prospective followup. *J Rheumatol* 1984; 11: 158-61.
38. MITCHELL DM, SPITZ PW, YOUNG DY, BLOCH DA, MCSHANE DJ, FRIES JF: Survival, prognosis, and causes of death in rheumatoid arthritis. *Arthritis Rheum* 1986; 29: 706-14.
39. FRIES J, BLOCH D, SPITZ P: Cancer in rheumatoid arthritis: a prospective long-term study of mortality. *Am J Med* 1985; 78: 56-9.
40. WICKS IP, MOORE J, FLEMING A: Australian mortality statistics for rheumatoid arthritis 1950-81: analysis of death certificate data. *Ann Rheum Dis* 1988; 47: 563-9.
41. WOLFE F, KLEINHEKSEL SM, CATHEY MA, HAWLEY DJ, SPITZ PW, FRIES JF: The clinical value of the Stanford health assessment questionnaire functional disability Index in patients with rheumatoid arthritis. *J Rheumatol* 1988; 15: 1480-8.
42. ERHARDT CC, MUMFORD PA, VENABLES PJW, MAINI RN: Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. *Ann Rheum Dis* 1989; 48: 7-13.
43. SAWAY PA, BLACKBURN WD, HALLA JT, ALARCÓN GS: Clinical characteristics affecting survival in patients with rheumatoid arthritis undergoing cervical spine surgery: a controlled study. *J Rheumatol* 1989; 16: 890-6.
44. KAZIS LE, ANDERSON JJ, MEENAN RF: Health status as a predictor of mortality in rheumatoid arthritis: a five-year study. *J Rheumatol* 1990; 17: 609-13.
45. LEHTINEN K, ISOMÄKI H: Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis. *J Rheumatol* 1991; 18: 524-9.
46. LEIGH JP, FRIES JF: Mortality predictors among 263 patients with rheumatoid arthritis. *J Rheumatol* 1991; 18: 1307-12.
47. JACOBSSON LT, KNOWLER WC, PILLEMER S *et al.*: Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. *Arthritis Rheum* 1993; 36: 1045-53.
48. WOLFE F, MITCHELL DM, SIBLEY JT *et al.*: The mortality of rheumatoid arthritis. *Arthritis Rheum* 1994; 37: 481-94.
49. COSTE J, JOUGLA E: Mortality from rheumatoid arthritis in France, 1970-1990. *Int J Epidemiol* 1994; 23: 545-52.
50. RADIS CD, KAHL LE, BAKER GL *et al.*: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. *Arthritis Rheum* 1995; 38: 1120-7.
51. MYLLYKANGAS-LUOSUJARVI R, AHO K, KAUTIAINEN H, ISOMÄKI H: Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. *Clin Exp Rheumatol* 1995; 13: 149-53.
52. MYLLYKANGAS-LUOSUJARVI R, AHO K, KAUTIAINEN H, ISOMAKI H: Cardiovascular mortality in women with rheumatoid arthritis. *J Rheumatol* 1995; 22: 1065-7.
53. MYLLYKANGAS-LUOSUJARVI R, AHO K, ISOMAKI H: Mortality from cancer in patients with rheumatoid arthritis. *Scand J Rheumatol* 1995; 24: 76-8.
54. NEVA MH, MYLLYKANGAS-LUOSUJARVI R, KAUTIAINEN H, KAUPPI M: Mortality associated with cervical spine disorders: a population-based study of 1666 patients with rheumatoid arthritis who died in Finland in 1989. *Rheumatology (Oxford)* 2001; 40: 123-7.
55. HELIÖVAARA M, AHO K, KNEKT P, AROMAA A, MAATELA J, REUNANEN A: Rheumatoid factor, chronic arthritis and mortality. *Ann Rheum Dis* 1995; 54: 811-4.
56. JONES M, SYMMONS D, FINN J, WOLFE F: Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. *Br J Rheumatol* 1996; 35: 738-45.
57. VOSKUYLAE, ZWINDERMAN AH, WESTEDT ML, VANDERBROUCKE JP, BREEDVELD FC, HAZES JMW: The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. *Arthritis Rheum* 1996; 39: 266-71.
58. CALLAHAN LF, CORDRAY DS, WELLS G, PINCUS T: Formal education and five-year mortality in rheumatoid arthritis: Mediation by helplessness scale scores. *Arthritis Care Res* 1996; 9: 463-72.
59. PINCUS T, KEYSOR J, SOKKA T, KRISHNAN E, CALLAHAN LF: Patient questionnaires and formal education level as prospective predictors of mortality over 10 years in 97% of 1416 patients with rheumatoid arthritis from 15 United States private practices. *J Rheumatol* 2004; 31: 229-34.
60. SWINSON DR, SYMMONS D, SURESH U, JONES M, BOOTH J: Decreased survival in patients with co-exist rheumatoid arthritis and bronchiectasis. *Br J Rheumatol* 1997; 36: 689-91.
61. CALLAHAN LF, PINCUS T, HUSTON JW, III, BROOKS RH, NANCE EP, JR., KAYE JJ: Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. *Arthritis Care Res* 1997; 10: 381-94.
62. KREMER JM: Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Followup after a mean of 13.3 years. *Arthritis Rheum* 1997; 40: 984-5.
63. WALLBERG-JONSSON S, OHMAN ML, DAHLQVIST SR: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. *J Rheumatol* 1997; 24: 445-51.
64. SÖDERLIN MK, NIEMINEN P, HAKALA M: Functional status predicts mortality in a community based rheumatoid arthritis population. *J Rheumatol* 1998; 25: 1895-9.
65. VAN DEN BORNE BE, LANDEWÉ RB, HOUKES I *et al.*: No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. *Arthritis Rheum* 1998; 41: 1930-7.
66. LINDQVIST E, EBERHARDT K: Mortality in rheumatoid arthritis patients with disease onset in the 1980s. *Ann Rheum Dis* 1999; 58: 11-4.
67. TURESSON C, JACOBSSON L, BERGSTROM U: Extra-articular rheumatoid arthritis: Prevalence and mortality. *Rheumatology* 1999; 38: 668-74.
68. SOKKA T, MÖTTÖNEN T, HANNONEN P: Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years. *Scand J Rheumatol* 1999; 28: 282-7.
69. GABRIEL SE, CROWSON CS, O'FALLON M: Mortality in rheumatoid arthritis: Have we

- made an impact in 4 decades? *J Rheumatol* 1999; 26: 2529-33.
70. MAIDEN N, CAPELL HA, MADHOK R, HAMPSON R, THOMSON EA: Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? *Ann Rheum Dis* 1999; 58: 525-9.
  71. WALLBERG-JONSSON S, JOHANSSON H, OHMAN ML, RANTAPAA-DAHLQVIST S: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. *J Rheumatol* 1999; 26: 2562-71.
  72. KRAUSE D, SCHLEUSSER B, HERBORN G, RAU R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. *Arthritis Rheum* 2000; 43: 14-21.
  73. KVALVIK AG, JONES MA, SYMMONS DPM: Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. *Scand J Rheumatol* 2000; 29: 29-37.
  74. KROOTEJ, VAN LEEUWEN MA, VAN RIJSWIJK MH *et al.*: No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. *Ann Rheum Dis* 2000; 59: 954-8.
  75. RIISE T, JACOBSEN BK, GRAN JT, HAGA HJ, ARNESEN E: Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. *Clin Rheumatol* 2001; 20: 123-7.
  76. CHEHATA JC, HASSELL AB, CLARKE SA *et al.*: Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. *Rheumatology* 2001; 40: 447-52.
  77. ISAACS JD, GREER S, SHARMA S *et al.*: Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. *Arthritis Rheum* 2001; 44: 1998-2008.
  78. LORENZI AR, CLARKE AM, WOOLDRIDGE T *et al.*: Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. *Arthritis Rheum* 2008; 58: 370-5.
  79. MARTÍNEZ MS, GARCÍA-MONFORTE A, RIVERA J: Survival study of rheumatoid arthritis patients in Madrid (Spain). A 9-year prospective follow-up. *Scand J Rheumatol* 2001; 30: 195-8.
  80. RIISE T, JACOBSEN BK, GRAN JT: High mortality in patients with rheumatoid arthritis and atlantoaxial subluxation. *J Rheumatol* 2001; 28: 2425-9.
  81. UHRIN Z, WANG BW, MATSUDA Y, STROBER S, GENOVESE MC: Treatment of rheumatoid arthritis with total lymphoid irradiation: long-term survival. *Arthritis Rheum* 2001; 44: 1525-8.
  82. CHEVREL G, JENVRIN C, MCGREGOR B, MIOSSEC P: Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. *Rheumatology* 2001; 40: 821-5.
  83. DORAN MF, POND GR, CROWSON CS, O'FALLON WM, GABRIEL SE: Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. *Arthritis Rheum* 2002; 46: 625-31.
  84. GABRIEL SE, CROWSON CS, KREMERS HM *et al.*: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. *Arthritis Rheum* 2003; 48: 54-8.
  85. TURESSON C, O'FALLON WM, CROWSON CS, GABRIEL SE, MATTESON EL: Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. *J Rheumatol* 2002; 29: 62-7.
  86. KREMERS HM, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE: Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. *Arthritis Rheum* 2004; 50: 3450-7.
  87. KREMERS HM, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE: Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2005; 52: 722-32.
  88. MARADIT-KREMERS H, CROWSON CS, NICOLA PJ *et al.*: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum* 2005; 52: 402-11.
  89. NICOLA PJ, CROWSON CS, MARADIT-KREMERS H *et al.*: Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. *Arthritis Rheum* 2006; 54: 60-7.
  90. YELIN E, TRUPIN L, WONG B, RUSH S: The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. *J Rheumatol* 2002; 29: 1851-7.
  91. CHOI HK, HERNÁN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet* 2002; 359: 1173-7.
  92. BJORNADAL L, BAECKLUND E, YIN L, GRANATH F, KLARESKOG L, EKBOM A: Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. *J Rheumatol* 2002; 29: 906-12.
  93. MIKULS TR, SAAG KG, CRISWELL LA *et al.*: Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. *Ann Rheum Dis* 2002; 61: 994-9.
  94. PELTOMAA R, PAIMELA L, KAUTIAINEN H, LEIRISALO-REPO M: Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. *Ann Rheum Dis* 2002; 61: 889-94.
  95. GOODSON NJ, WILES NJ, LUNT M, BARRETT EM, SILMAN AJ, SYMMONS DPM: Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients. *Arthritis Rheum* 2002; 46: 2010-9.
  96. FARRAGHER TM, LUNT M, BUNN DK, SILMAN AJ, SYMMONS DP: Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. *Ann Rheum Dis* 2007; 66: 486-92.
  97. FARRAGHER TM, GOODSON NJ, NASEEM H *et al.*: Association of the *HLA-DRB1* gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. *Arthritis Rheum* 2008; 58: 359-69.
  98. NAZ SM, FARRAGHER TM, BUNN DK, SYMMONS DP, BRUCE IN: The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. *Arthritis Rheum* 2008; 58: 985-9.
  99. WATSON DJ, RHODES T, GUESS HA: All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. *J Rheumatol* 2003; 30: 1196-202.
  100. NAVARRO-CANO G, DEL RINCÓN I, POGOSIAN S, ROLDÁN JF, ESCALANTE A: Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. *Arthritis Rheum* 2003; 48: 2425-33.
  101. THOMAS E, SYMMONS DP, BREWSTER DH, BLACK RJ, MACFARLANE GJ: National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. *J Rheumatol* 2003; 30: 958-65.
  102. WOLFE F, MICHAUD K, GEFELLER O, CHOI HK: Predicting mortality in patients with rheumatoid arthritis. *Arthritis Rheum* 2003; 48: 1530-42.
  103. ANG DC, CHOI H, KROENKE K, WOLFE F: Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. *J Rheumatol* 2005; 32: 1013-9.
  104. SOLOMON DH, KARLSON EW, RIMM EB *et al.*: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation* 2003; 107: 1303-7.
  105. SIHVONEN S, KORPELA M, MUSTONEN J, LAIPPALA P, PASTERNAK A: Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. *Nephron Clin Pract* 2004; 96: c107-14.
  106. SIHVONEN S, KORPELA M, MUSTILA A, MUSTONEN J: The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. *J Rheumatol* 2005; 32: 2089-94.
  107. SIHVONEN S, KORPELA M, MUSTONEN J, HUHTALA H, KARSTILA K, PASTERNAK A: Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. *J Rheumatol* 2006; 33: 1740-6.
  108. KRISHNAN E, LINGALA VB, SINGH G: Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. *Circulation* 2004; 110: 1774-9.
  109. SOKKA T, HAKKINEN A, KRISHNAN E, HANNONEN P: Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. *Ann Rheum Dis* 2004; 63: 494-7.
  110. KAUPPI M, SOKKA T, HANNONEN P: Survey nonresponse is associated with increased mortality in patients with rheumatoid arthritis.



- and in a community population. *J Rheumatol* 2005; 32: 807-10.
111. BOOK C, SAXNE T, JACOBSSON LTH: Prediction of mortality in rheumatoid arthritis based on disease activity markers. *J Rheumatol* 2005; 32: 430-4.
  112. GOODSON N, MARKS J, LUNT M, SYMMONS D: Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. *Ann Rheum Dis* 2005; 64: 1595-601.
  113. HAKODA M, OIWA H, KASAGI F *et al.*: Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study. *Ann Rheum Dis* 2005; 64: 1451-5.
  114. ESCALANTE A, HAAS RW, DEL RINCÓN I: Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. *Arch Intern Med* 2005; 165: 1624-9.
  115. RONKAINEN A, NISKANEN M, AUVINEN A, AALTO J, LUOSUJARVI R: Cervical spine surgery in patients with rheumatoid arthritis: longterm mortality and its determinants. *J Rheumatol* 2006; 33: 517-22.
  116. CARMONA L, DESCALZO MA, PEREZ-PAMPIN E *et al.*: All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. *Ann Rheum Dis* 2007; 66: 880-5.
  117. ABÁSOLO L, JÚDEZ E, DESCALZO MA *et al.*: Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. *Semin Arthritis Rheum* 2007; 37: 388-97.
  118. JACOBSSON LT, TURESSON C, NILSSON JA *et al.*: Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. *Ann Rheum Dis* 2007; 66: 670-5.
  119. GONZALEZ A, MARADIT KREMERS H, CROWSON CS *et al.*: The widening mortality gap between rheumatoid arthritis patients and the general population. *Arthritis Rheum* 2007; 56: 3583-7.
  120. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ *et al.*: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. *Arthritis Rheum* 2007; 57: 125-32.
  121. YOUNG A, KODURI G, BATLEY M *et al.*: Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. *Rheumatology (Oxford)* 2007; 46: 350-7.
  122. MATTEY DL, THOMSON W, OLLIER WE *et al.*: Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. *Arthritis Rheum* 2007; 56: 1408-16.
  123. MATTEY DL, GLOSSOP JR, NIXON NB, DAWES PT: Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. *Arthritis Rheum* 2007; 56: 3940-8.
  124. NIKOLAISEN C, FIGENSCHAU Y, NOSSENT JC: Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. *J Rheumatol* 2008; 35: 380-6.
  125. SOKKA T, KAUTIAINEN H, HANNONEN P, PINCUS T: Changes in health assessment questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. *Arthritis Rheum* 2006; 54: 3113-8.
  126. AVALOS I, RHO YH, CHUNG CP, STEIN CM: Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. *Clin Exp Rheumatol* 2008; 26 (Suppl. 51): S5-S13.
  127. PINCUS T, CALLAHAN LF: Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. *J Rheumatol* 1986; 13: 841-5.
  128. PINCUS T, CALLAHAN LF: Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. *Scand J Rheumatol* 1989; 18 (Suppl. 79): 67-96.
  129. PINCUS T, CALLAHAN LF: The 'side effects' of rheumatoid arthritis: Joint destruction, disability and early mortality. *Br J Rheumatol* 1993; 32: (Suppl.1): 28-37.
  130. CALLAHAN LF, PINCUS T: Mortality in rheumatic diseases. *Arthritis Care Res* 1995; 8: 229-41.
  131. PINCUS T, SOKKA T: Quantitative target values of predictors of mortality in rheumatoid arthritis as possible goals for therapeutic interventions: an alternative approach to remission or ACR20 responses? *J Rheumatol* 2001; 28: 1723-34.
  132. SOKKA T, HAUGEBERG G, PINCUS T: Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUESTRA global perspective. *Clin Exp Rheumatol* 2007; 25 (Suppl. 47): 86-97.
  133. LINDAHL BI, ALLANDER E: Problems in the classification of cause of death diagnoses affecting the reliability of mortality statistics for rheumatoid arthritis. *J Chronic Dis* 1985; 38: 409-18.
  134. SYMMONS DP: Mortality in rheumatoid arthritis. *Br J Rheumatol* 1988; 27: 44-54.
  135. MYLLYKANGAS-LUOSUJARVI RA, AHO K, ISOMÄKI HA: Mortality in rheumatoid arthritis. *Semin Arthritis Rheum* 1995; 25: 193-202.
  136. WARD MM: Recent improvements in survival in patients with rheumatoid arthritis: Better outcomes or different study designs? *Arthritis Rheum* 2001; 44: 1467-9.
  137. DIXON WG, SYMMONS DP: What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. *Ann Rheum Dis* 2007; 66: 1132-6.
  138. AKHAVANI MA, LARSEN H, PALEOLOG E: Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis. *Scand J Rheumatol* 2007; 36: 83-90.
  139. NAZ SM, SYMMONS DP: Mortality in established rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2007; 21: 871-83.
  140. WOLFE F, PINCUS T: Listening to the patient: A practical guide to self-report questionnaires in clinical care. *Arthritis Rheum* 1999; 42: 1797-808.
  141. PINCUS T: Documenting quality management in rheumatic disease: Are patient questionnaires the best (and only) method? *Arthritis Care Res* 1996; 9: 339-48.
  142. JOINT NATIONAL COMMITTEE ON PREVENTION DEATH/HBP, NATIONAL HIGH BLOOD PRESSURE EDUCATION PROGRAM COORDINATING COMMITTEE: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1997; 157: 2413-46.
  143. AMERICAN DIABETES ASSOCIATION: Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 2000; 23: S32-S42.
  144. MÖTTÖNEN T, HANNONEN P, LEIRISALO-REPO M *et al.*: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. *Lancet* 1999; 353: 1568-73.
  145. PUOLAKKA K, KAUTIAINEN H, MÖTTÖNEN T *et al.*: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. *Arthritis Rheum* 2005; 52: 36-41.
  146. GRIGOR C, CAPELL H, STIRLING A *et al.*: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet* 2004; 364: 263-9.
  147. GOEKOOP-RUITERMAN YPM, DE VRIES-BOUWSTRA JK, ALLAART CF *et al.*: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum* 2005; 52: 3381-90.
  148. GOEKOOP-RUITERMAN YPM, DE VRIES-BOUWSTRA JK, ALLAART CF *et al.*: Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2007; 146: 406-15.
  149. VERSTAPPEN SMM, JACOBS JWG, VAN DER VEEN MJ *et al.*: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis* 2007; 66: 1443-9.
  150. HETLAND ML, STENGAARD-PEDERSEN K, JUNKER P *et al.*: Aggressive combination therapy with intraarticular glucocorticoid injections and conventional DMARDs in early rheumatoid arthritis Two Year Clinical and Radiographic Results From The CIMESTRA Study. *Ann Rheum Dis* 2007. Ref Type: Abstract
  151. HETLAND ML, EJBJERG BJ, HORSLEV-PETERSEN K *et al.*: MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2 year randomized controlled trial (CIMESTRA). *Ann Rheum Dis* 2008; Apr 3 [Epub ahead of print].
  152. HETLAND ML, STENGAARD-PEDERSEN K,

- JUNKER P *et al.*: Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. *Ann Rheum Dis* 2008; 67: 815-22.
153. FELSON DT, ANDERSON JJ, BOERS M *et al.*: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. *Arthritis Rheum* 1993; 36: 729-40.
154. TUGWELL P, BOERS M: OMERACT Committee. Proceedings of the OMERACT Conferences on outcome measures in rheumatoid arthritis clinical trials, Maastricht, Netherlands. *J Rheumatol* 1993; 20: 527-91.
155. VAN RIEL PLCM: Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis (Editorial). *Br J Rheumatol* 1992; 31: 793-4.
156. BOERS M, TUGWELL P, FELSON DT *et al.*: World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. *J Rheumatol* 1994; 21 (Suppl. 41): 86-9.
157. PINALS RS, MASI AT, LARSEN RA *et al.*: Preliminary criteria for clinical remission in rheumatoid arthritis. *Arthritis Rheum* 1981; 24: 1308-15.
158. SOKKA T, MAKINEN H, HANNONEN P, PINCUS T: Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. *Rheumatology* (Oxford) 2007; 46: 1020-3.
159. WOLFE F, HAWLEY DJ: Remission in rheumatoid arthritis. *J Rheumatol* 1985; 12: 245-52.
160. MAKINEN H, HANNONEN P, SOKKA T: Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomized clinical trials for the rate of remission. *Clin Exp Rheumatol* 2006; 24 (Suppl. 43): S22-S28.
161. VAN DER HEIJDE DMFM, VAN'T HOF MA, VAN RIEL PLCM *et al.*: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Ann Rheum Dis* 1990; 49: 916-20.
162. VAN DER HEIJDE DMFM, VAN'T HOF M, VAN RIEL PLCM, VAN DE PUTTE LBA: Development of a disease activity score based on judgment in clinical practice by rheumatologists. *J Rheumatol* 1993; 20: 579-81.
163. FRANSEN J, VAN RIEL PLCM: DAS remission cut points. *Clin Exp Rheumatol* 2006; 24 (Suppl. 43): S29-S32.
164. ALETAHA D, SMOLEN J: The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. *Clin Exp Rheumatol* 2005; 23: S100-S108.
165. ALETAHA D, WARD MM, MACHOLD KP, NELL VP, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. *Arthritis Rheum* 2005; 52: 2625-36.
166. PINCUS T, BERGMAN MJ, YAZICI Y, HINES P, RAGHUPATHI K, MACLEAN R: An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. *Rheumatology* (Oxford) 2008; 47: 345-9.
167. PINCUS T, SWEARINGEN CJ, BERGMAN M, YAZICI Y: RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to DAS and CDAI categories. *J Rheumatol* 2008; in press.
168. PINCUS T, KAVANAUGH A, ALETAHA D, SMOLEN J: Complexities in defining remission in rheumatic diseases. *Clin Exp Rheumatol* 2006; 24 (Suppl. 43): S1-S6.
169. SINGER RB: Mortality in rheumatoid arthritis: experience in four clinical series compared with the experience in the 1983 medical impairment study. *J Insur Med* 1998; 30: 88-95.
170. MATTESON EL, WEYAND CM, FULBRIGHT JW, CHRISTIANSON TJH, MCCLELLAND RL, GORONZY JJ: How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial. *Rheumatology* 2004; 43: 619-25.
171. WONG JB, RAMEY DR, SINGH G: Long-term morbidity, mortality, and economics of rheumatoid arthritis. *Arthritis Rheum* 2001; 44: 2746-9.
172. PINCUS T, GIBOFSKY A, WEINBLATT ME: Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. *Arthritis Rheum* 2002; 46: 851-4.
173. NISHIMURA K, SUGIYAMA D, KOGATA Y *et al.*: Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. *Ann Intern Med* 2007; 146: 797-808.
174. WOLFE F, MICHAUD K: The clinical and research significance of the erythrocyte sedimentation rate. *J Rheumatol* 1994; 21: 1227-37.
175. ROPES MW, BENNETT GA, COBB S, JACOX RF, JESSAR RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. *Bull Rheum Dis* 1958; 9: 175-6.
176. O'SULLIVAN JB, CATHCART ES: The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. *Ann Intern Med* 1972; 76: 573-7.
177. MIKKELSEN WM, DODGE H: A four year follow-up of suspected rheumatoid arthritis: the Tecumseh, Michigan, community health study. *Arthritis Rheum* 1969; 12: 87-91.
178. LICHTENSTEIN MJ, PINCUS T: Rheumatoid arthritis identified in population based cross sectional studies: Low prevalence of rheumatoid factor. *J Rheumatol* 1991; 18: 989-93.
179. VALKENBERG HA, BALL J, BURCH TA, BENNETT PH, LAWRENCE JS: Rheumatoid factors in a rural population. *Ann Rheum Dis* 1966; 25: 497-507.
180. MIKKELSEN WM, DODGE HJ, DUFF IF, KATO H: Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959-60. *J Chronic Dis* 1967; 20: 351-69.
181. ADLER E, ABRAMSON JH, GOLDBERG R, ELKAN Z, BEN HADOR S: Rheumatoid arthritis in a Jerusalem population: 2. Epidemiology of rheumatoid factors. *Am J Epidemiol* 1967; 85: 378-86.
182. BURCH TA, O'BRIEN WM, LAWRENCE JS, BENNETT PH, BUNIM JJ: A comparison of the prevalence of rheumatoid arthritis (R.A.) and rheumatoid factor (R.F.) in Indian tribes living in Montana mountains and in Arizona desert. *Arthritis Rheuma* 1963; 6: 765.
183. AHO K, JULKUNEN H, LAINE V, RIPATTI N, WAGER O: Clinical evaluation of the serological tests in rheumatoid arthritis. 1. Normal series collected by random sampling. *Acta Rheumatol Scand* 1961; 7: 201-8.
184. SOKKA T, PINCUS T: A historical perspective concerning population-based and clinical studies of early arthritis and early rheumatoid arthritis. *Clin Exp Rheumatol* 2003; 21: S5-S14.
185. VAN DER HORST-BRUIJNSMA IE, SPEYER I, VISSER H, BREEDVELD FC, HAZES JMW: Diagnosis and course of early-onset arthritis: Results of a special early arthritis clinic compared to routine patient care. *Br J Rheumatol* 1998; 37: 1084-8.
186. VAN AKEN J, VAN BILSEN JHM, ALLAART CF, HUIZINGA TWJ, BREEDVELD FC: The Leiden Early Arthritis Clinic. *Clin Exp Rheumatol* 2003; 21: S100-S105.
187. MACHOLD KP, NELL VPK, STAMM TA, EBERL G, STEINER G, SMOLEN JS: The Austrian Early Arthritis Registry. *Clin Exp Rheumatol* 2003; 21: S113-S117.
188. SOKKA T, KAUTIAINEN H, TOLOZA S *et al.*: QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. *Ann Rheum Dis* 2007; 66: 1491-6.
189. CALLAHAN LF, SMITH WJ, PINCUS T: Self-report questionnaires in five rheumatic diseases: Comparisons of health status constructs and associations with formal education level. *Arthritis Care Res* 1989; 2: 122-31.
190. SOKKA T, PINCUS T: Improved outcomes in consecutive patients with rheumatoid arthritis in 2000 compared to 1985, according to an identical cross sectional quantitative standard protocol to evaluate rheumatoid arthritis (SPERA). *Arthritis Rheum* 2002; 46: S242.
191. SOKKA T, PINCUS T: Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. *Rheumatology* (Oxford) 2008; Aug 7. [Epub ahead of print].
192. SILMAN AJ: The changing face of rheumatoid arthritis: why the decline in incidence? *Arthritis Rheum* 2002; 46: 579-81.
193. GERBER Y, JACOBSEN SJ, FRYE RL, WESTON SA, KILLIAN JM, ROGER VL: Secular trends in deaths from cardiovascular diseases: a 25-year community study. *Circulation* 2006; 113: 2285-92.
194. PINCUS T, YAZICI Y, BERGMAN M, MACLEAN R, HARRINGTON T: A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal

- joint counts, based on quantitative Routine Assessment of Patient Index Data (RAPID) scores on a Multidimensional Health Assessment Questionnaire (MDHAQ). *Best Pract Res Clin Rheumatol* 2007; 21: 789-804.
195. PINCUS T, SOKKA T: Should an order to "monitor long-term vital signs," including mortality outcomes, be as routine as an order for a laboratory test in patients with rheumatic diseases? *Clin Exp Rheumatol* 2008; 26 (Suppl. 51): S21-S24.
  196. VETERANS ADMINISTRATION COOPERATIVE STUDY ON ANTIHYPERTENSIVE AGENT: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. *JAMA* 1970; 213: 1143-50.
  197. ROSS SD, ALLEN IE, CONNELLY JE *et al.*: Clinical outcomes in statin treatment trials. *Arch Intern Med* 1999; 159: 1793-802.
  198. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; 329: 977-86.
  199. STEIN CM, PINCUS T: Placebo-controlled studies in rheumatoid arthritis: Ethical issues. *Lancet* 1999; 353: 400-3.
  200. GOODSON NJ, SYMMONS DP, SCOTT DG, BUNN D, LUNT M, SILMAN AJ: Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. *Arthritis Rheum* 2005; 52: 2293-9.
  201. ASKLING J, FORED CM, BAECKLUND E *et al.*: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. *Ann Rheum Dis* 2005; 64:1414-20.
  202. ASKLING J, FORED CM, BRANDT L *et al.*: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. *Ann Rheum Dis* 2005; 64: 1421-6.
  203. THOMAS E, BREWSTER DH, BLACK RJ, MACFARLANE GJ: Risk of malignancy among patients with rheumatic conditions. *Int J Cancer* 2000; 88: 497-502.
  204. CARSTAIRS V, MORRIS R: Deprivation: explaining differences in mortality between Scotland and England and Wales. *Br Med J* 1989; 299: 886-9.
  205. ABELSON B, RUPEL A, PINCUS T: Limitations of a biomedical model to explain socioeconomic disparities in mortality of rheumatic and cardiovascular diseases. *Clin Exp Rheumatol* 2008; 26 (Suppl. 51) S25-S34.
  206. PINCUS T, CALLAHAN LF, BROOKS RH, FUCHS HA, OLSEN NJ, KAYE JJ: Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. *Ann Intern Med* 1989; 110: 259-66.
  207. OLSEN NJ, CALLAHAN LF, BROOKS RH *et al.*: Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. *Am J Med* 1988; 84: 257-64.
  208. WEYAND CM, HICOK KC, CONN DL, GORONZY JJ: The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. *Ann Intern Med* 1992; 117: 801-6.
  209. OLLIER W, VENABLES PJW, MUMFORD PA *et al.*: HLA antigen associations with extra-articular rheumatoid arthritis. *Tissue Antigens* 1984; 24: 279-91.
  210. FUCHS HA, BROOKS RH, CALLAHAN LF, PINCUS T: A simplified twenty-eight joint quantitative articular index in rheumatoid arthritis. *Arthritis Rheum* 1989; 32: 531-7.
  211. MULHERIN D, FITZGERALD O, BRESNIHAN B: Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that pathogenesis of synovial inflammation and articular erosion may differ. *Br J Rheumatol* 1996; 35: 1263-8.
  212. PINCUS T, CALLAHAN LF: Rheumatology Function Tests: Grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis. *J Rheumatol* 1992; 19: 1051-7.
  213. PINCUS T: Rheumatology function tests: quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases. *Clin Exp Rheumatol* 2005; 23: S85-S89.
  214. TUGWELL P, WELLS G, STRAND V *et al.*: Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. *Arthritis Rheum* 2000; 43: 506-14.
  215. PINCUS T, AMARA I, SEGURADO OG, BERGMAN M, KOCH GG: Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. *J Rheumatol* 2008; 35: 201-5.
  216. WOLFE F, CATHEY MA, KLEINHEKSEL SM: Fibrositis (fibromyalgia) in rheumatoid arthritis. *J Rheumatol* 1984; 11: 814-8.
  217. MYLLYKANGAS-LUOSUJÄRVI R, AHO K, ISOMÄKI H: Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. *J Rheumatol* 1995; 22: 2214-7.
  218. WASENBERG S, RAU R, STEINFELD P, ZEIDLER H: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2005; 52: 3371-80.
  219. BUTTGEREIT F, SAAG KG, CUTOLO M, DA SILVA JAP, BIJLSMA JWJ: The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. *Scan J Rheumatol* 2005; 34: 14-21.
  220. SVENSSON B, BOONEN A, ALBERTSSON K, VAN DER HEIJD D, KELLER C, HAFSTROM I: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. *Arthritis Rheum* 2005; 52: 3360-70.
  221. LUUKKAINEN R, ISOMÄKI H, KAJANDER A: Effect of gold treatment on the progression of erosions in RA patients. *Scand J Rheumatol* 1977; 6: 123-7.